

THE UNIVERSITY OF BRITISH COLUMBIA
Curriculum Vitae for Faculty Members

Date: January 2015

Initials: LDL

1. **SURNAME:** Lynd **FIRST NAME:** Larry
MIDDLE NAME(S): David
2. **DEPARTMENT/SCHOOL:** Pharmaceutical Sciences
3. **FACULTY:** Pharmaceutical Sciences
4. **PRESENT RANK:** Professor **SINCE:** July 2014

5. **POST-SECONDARY EDUCATION**

University or Institution	Degree/ Diploma	Subject Area	Dates
Centre for Teaching and Academic Growth, University of British Columbia, Vancouver, BC	Certificate	Teaching and Learning on Higher Education	2005 - 2006
Centre for Evaluation of Medicines, McMaster University & St. Joseph's Hospital, Hamilton, ON, Canada	Post- doctoral Fellow ¹	Health Economics	2002 - 2004
University of British Columbia Vancouver, BC, Canada	Ph.D. ²	Health Care & Epidemiology	1997 - 2002
St. Paul's Hospital, Vancouver, BC, Canada	Residency Certificate	Hospital Pharmacy Residency	1986 - 1987
University of Saskatchewan, Saskatoon, SK, Canada	BSP	Pharmacy	1982 - 1986

¹Courses: Principles of Health Economics, Advanced Economic Methods, Advanced Economic Modeling.

²Courses: Health Economics, Microeconomics, Health Services Research, Demography, Basic Statistics, Advanced Statistics/Multivariate Analysis, Longitudinal/Repeated Measures Analysis, Clinical Epidemiology, Population Health, Pharmacoepidemiology 1, 2, 3 and 4 (McGill University).

Title of Dissertation and Name of Supervisor

Title: An evaluation of the determinants of asthma management and asthma control: a study of British Columbia asthmatics.

Supervisor: Aslam Anis

Special Professional Qualifications

Licensure – BC College of Pharmacists

Certified Specialist – Poison Information and Toxicology, American Association of Poison Control Centers
Member of Register of Pharmacists of the Pharmacy Examining Board of Canada (RPEBC)

6. EMPLOYMENT RECORD

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
Centre for Evaluation of Medicines, McMaster University/ St. Joseph's Hospital, Hamilton, ON	Post-doctoral Fellow	2002 - 2004
BC Regional Adverse Drug Reaction Reporting Program, BC Drug and Poison Information Centre & Health Canada, Drugs Directorate, Therapeutic Products Program	Program Coordinator	1995 - 1997
BC Drug and Poison Information Centre	Drug and Poison Information Specialist	1990 - 2002
Royal University Hospital, Saskatoon, SK.	Staff Pharmacist	1987 - 1990

(b) *At UBC*

Rank or Title	Dates
Director, Collaboration for Outcomes Research and Evaluation	July 2014 -
Professor (with Tenure), Pharmaceutical Sciences	July 2014 -
Associate Professor (with Tenure), Pharmaceutical Sciences	2009 – June 2014
Associate Director, Collaboration for Outcomes Research and Evaluation	2004 – June 2014
Scientist, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute	2004 - 2007; 2010 - present
Scientist, Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute	2007 - present
Assistant Professor (Tenure Track), Pharmaceutical Sciences	2004 - 2009
Associate Head, Health Economics Program, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute	2004 - 2007
Clinical Instructor	1990 - 2002

(c) *Date of Granting Tenure at UBC: **July 2009***

(d) *Other Academic Affiliations*

Scholar, Peter Wall Institute for Advanced Studies, UBC (September 1, 2011 - ongoing)
Adjunct Professor, Dept. of Epidemiology and Biostatistics, Erasmus University Rotterdam, The Netherlands
Affiliate, Centre for Health Care Management, UBC

7. LEAVES OF ABSENCE

July 1, 2014 to December 31, 2014 - Sabbatical

8. TEACHING

(a) *Areas of Special Interest and Accomplishments*

I was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes for Health Research New Investigator during the first five years of my academic appointment at UBC. The intention of these peer-reviewed, competitive salary awards is to facilitate and promote my research career. As such, both awards stipulated limitations to the amount of time that can be committed to teaching so that I could focus on developing my research program. Despite these restrictions on my teaching, I continued to

teach as much as these awards permit. In doing so, I developed two new courses in the faculty, and continue to teach at both the graduate and undergraduate levels.

Relevant Education and Teaching Approach

Over the course of my post-graduate career, I have been involved in numerous courses related to instructional and lecture skills and techniques. As a clinical faculty member in Faculty of Pharmaceutical Sciences and mentor for PharmD students and hospital pharmacy residents, I have participated in a number of workshops designed for the development of preceptors directly involved in the mentorship of these students. During my post-graduate and post-doctoral training, I was also involved in seminars and symposia on instructional methods aimed at enhancing instructional skills and was mentored by two excellent teachers, Dr. Aslam Anis and Dr. Bernie O'Brien. My exposure to these mentors has helped me to develop my own personal approach to teaching and higher education that involves developing a connection with the students, identifying their needs and goals, and motivating them to strive to meet or exceed their own personal expectations.

Outside of academia, I am a certified intermediate-level hockey coach, a program that involves instruction on teaching techniques, mentorship, communication skills, and conflict resolution methods. Having now coached hockey at many levels for many years, I have applied and developed many different instructional techniques (e.g. building on components of certain skills over time) and motivational approaches that are also applicable to the university classroom or one-to-one mentorship of trainees.

Context of University Teaching

I have been involved in various facets of university teaching, including didactic instruction at both the undergraduate and graduate levels, one-to-one mentorship of undergraduate directed studies students, hospital pharmacy and medical residents, and PharmD students. I have also been involved in the continuing education of pharmacy and medical professionals in workshops and conferences.

In the undergraduate curriculum, I am involved in teaching courses within the Pharmaceutical Sciences curriculum in which I have taught in classes of approximately 160 students in the area of health outcomes assessment and pharmacoeconomics. I also developed, and am currently teaching a 4th year undergraduate elective course in pharmacoeconomics which has now been offered since the winter term of 2006.

At the graduate level, I lead the development of a new 6 credit course in the Doctor of Pharmacy Program (PHAR506). Since the inception of the PharmD program at UBC, PharmD students were enrolled in HCEP400 (Basic Biostatistics) and HCEP 502 (Clinical Trials). Having taken both of the courses, I was aware that the content and objectives of these courses did not meet the learning needs of Doctor of Pharmacy Students. Therefore, in collaboration with Dr. Carlo Marra, I undertook a review of the current courses, and an environmental scan of curricula from PharmD programs throughout North America, and developed a new 6-credit course encompassing biostatistics, epidemiology, and health economics – PHAR506 Critical Appraisal of Pharmacotherapy Literature. This course was run for two years as a directed studies course, after which we applied for, and received UBC Senate approval as an official course in the PharmD curriculum.

Finally, I have led discussions in economic evaluation and quantitative benefit-risk analysis in the Department of Health Care and Epidemiology in the Faculty of Medicine (approximately 15 students). Outside of the core courses within the Faculty, the students enrolled in the course often come from health care backgrounds prior to entering pharmacy, and have specific interests in health economics, epidemiology, and outcomes research. Exposing students to these concepts has been a valuable approach to attracting directed studies and summer research program students as well.

Approach to Teaching & Learning

Philosophy of teaching

I believe that any educational process must involve the participation of both the teacher and the student, and that the balance between a learner-centred and a teaching-centred teaching approach must be adopted, depending on the learning situation. In addition to teaching some larger classes, I have been fortunate to be involved in a lot of one-to-one mentorships with hospital pharmacy residents, Pharm.D. students, and graduate students, as well as teaching in smaller classes (of 15 – 25 students) and thus, have always had the opportunity to actively engage the students in the learning process using a learning-centred approach. Thus, when mentoring one-to-one, my teaching philosophy entails actively engaging the student in the learning progress rather than merely using didactic methods, and to involve students in active discussion and dialogue which facilitates the development and fostering of the students critical thinking skills. I also try to integrate this philosophy into the classroom environment as well.

Beliefs

Dedicated to being a life-long learner, my philosophy of teaching embraces the concept that learning is an active process that encompasses both the educator and the student. The learning environment (whether in the classroom or in an experiential setting) that I try to create encourages students to pursue their goals and express their individual ideas through intellectual discussion. Students are encouraged to take responsibility for their education and to work with me to enrich their educational experiences.

My goal is to work with students through interactions in and outside of class to explain the course materials, untangle the confusion, and guide students to meet their goals. My responsibility is to help my students learn – I do this by building on course materials and texts, integrating recent scientific findings into my teaching, encouraging the use of external resources, and trying to impart the skills of critical thinking in my students. As the scope of my professional and research interests has increased to include areas that are not traditionally part of the pharmacy curriculum, the challenge of presenting this material to both undergraduate and Doctor of Pharmacy students has increased. However, I find that, with my clinical background, I have the ability to put the issues and concepts that I am teaching into perspective such that students with a health sciences background can easily comprehend.

As a quantitative person with skills and training in this area, my overall teaching philosophy is firmly grounded within the philosophical domains of apprenticeship and development, with some components of nurturing. I find that my teaching mostly focuses on these aspects with little emphasis on trying to implement social reform through my teaching. This void is one area that I would like to fill as I move forward with my teaching within the university. Social reform is vital in the profession of pharmacy as the profession is moving towards assuming more responsibility for the primary care of patients, and is particularly germane to one of my specific areas of research interest, specifically policy development for orphan drugs. Part of this process will be to educate and motivate students to be the vehicle to implement change once they graduate. As young practitioners, many are filled with idealism and dreams that may not necessarily be feasible in practice. I feel that part of my role as an educator is to illustrate the current state of affairs with respect to the profession, establish feasible and realistic goals that students can hope to achieve within the short and long term, and to identify the challenges that the profession is faced with.

Actions

When lecturing to large classes in the undergraduate curriculum, I am often introducing new concepts and ideas that many students have not encountered. As such, these lectures are often teaching-centred such that a structured presentation is delivered. However, one of the goals of these lectures is to invigorate students and pique their interest in the content such that they will either further investigate on their own, enroll in elective courses in higher levels, or pursue directed studies or summer studentships. Therefore, I strive to give practical examples (actual topical situations that exist in the Canadian and other countries' health care systems) and assign problems (i.e. evaluate an article from the lay media about "health hype") that help them realize the importance of the material to the profession of pharmacy. Whether in a didactic setting or a situation of one-to-one mentorship, my general approach entails "teaching through example". More specifically, I use textbooks and course materials that I have developed to illustrate specific concepts, and then integrate scientific findings and specific real-world examples of where the concepts have been demonstrated.

I strongly believe that students may have different objectives for taking the courses that they choose. Therefore, when possible I engage the student to establish specific goals and objectives for their individual learning experience. Then, as a teacher, I strive to ensure that the student realizes his or her own specific goals. Specifically, for senior undergraduate, Pharm.D., and other graduate students where I am more closely involved with the students, I adopt a discussion group approach where students are assigned one or two short pre-readings on the content area and instructed to come prepared to discuss the material. Examples are given which illustrate the practical application of the content of the pre-readings and case-studies are completed during the session to help them develop critical thinking and problem-solving skills. As such, I try to keep these sessions as “learner-centered” as possible.

(b) *Courses Taught at UBC**

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2013 (W)	PHAR 456	39	12	24	6		
2013 (W)	PHAR506	39	8	30			
2012 (W)	PHAR 456	39	14	30			
2012 (W)	PHAR 506	78	8	48	6		
2012 (W)	ECON 384	39	60	2			
2011 (W)	PHAR 506	78	8	40			
2011 (W)	PHAR 456	39	23	16	8		
2010 (W)	PHAR 506	78	8	40			
2010 (W)	PHAR 456	39	23	16	8		
2009 (W)	HCEP 541	39	12	3			
2009 (W)	HCEP 580B	39	6	3			
2009 (W)	DPAS 410	1.5	160	1.5			
2009 (W)	PHAR 506	39	8	25.5			
2009 (W)	PHAR 456	39	28	16	8		
2008 (W)	PHAR 405B	39	8	4			
2008 (W)	PHAR 535B	39	15	4			
2008 (W)	PHAR 450B	39	21	15	6		
2007 (W)	PHAR 201	39	160	3			
2007 (W)	PHAR 450B	39	17	14	6		
2007 (W)	PHAR 453	39	1				15
2007 (W)	PHAR 399	39	152	1			
2007 (W)	PHAR 590	39	17	3			
2007 (W)	PHAR 535B	39	7	4			
2007 (W)	DPAS 410	1.5	160	1.5			
2007 (W)	HCEP 580	39	10	3			
2007 (W)	HCEP 541	39	13	3			
2006 (W)	PHAR 450B	39	13	14	6		
2006 (W)	PHAR 201	39	120	2			
2006 (W)	PHAR 590	39	10	4			
2006 (W)	DPAS 410	39	160	1.5			
2006 (W)	HCEP 580B	39	5	1			
2005 (W)	HCEP 580B	39	8	1			
2005 (W)	DPAS 410	39	280	1			
2005 (W) Term 2	PHAR 450B	39	17	14	6	-----	-----
2005 (W) Term 1	PHAR 450B	39	3	14	6	-----	-----
2005 (W)	Pharm 201	39	120	3	-----	-----	-----

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2004	HRM789 (Mac)	3	16	3			
2003	Phm435 (UofT)	2	140	2			
2001 (W)	PHAR 535B	6	6	6	-----	-----	-----
2000 (W)	PHAR 535B	6	6	6	-----	-----	-----
1999 (W)	PHAR 535B	6	6	6	-----	-----	-----
1994 (W)	PHAR 200	12	24	----	-----	12	-----
1994 (W)	PHAR 400	12	8	----	12	----	----
1993 (W)	PHAR 200	15	24	----	-----	15	-----
1993 (W)	PHAR 406	12	8	----	12	----	----

*No courses taught W2013 due to study leave July 1 - Dec 31, 2013.

Courses currently taught: PHAR 456 – Introduction to Health Technology Assessment and Pharmacoeconomics, PHAR 506 – Critical Appraisal of Pharmacotherapy Literature, HCEP 541 – Health Services Research and Economic Evaluation, HCEP 580 – Pharmacoepidemiology.

(c) *Graduate Students Supervised*

M.Sc. and Ph.D. Graduate Students Supervised

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Jiemin Zhou	M.Sc.	09/2014		Committee Chair
Vongai Nyamandi	Ph.D.	09/2014		Committee Chair
Mohamed Wehbe	Ph.D.	09/2014		Committee Chair
Jialin Xu	Ph.D.	09/2014		Committee Chair
Nicole Tsao, MSc ¹⁰	Ph.D., Faculty of Pharmaceutical Sciences	09/2014		Supervisor
Anik Patel, MHA, BSc (Pharm)	Ph.D., Faculty of Medicine	09/2014		Co-Supervisor
Clea Machold	M.A., School of Journalism	09/2013		Co-Supervisor
Katelyn Verstraten	M.A., School of Journalism	09/2013	04/2014	Co-Supervisor
Celestin Hategakimana, MD ¹	M.Sc., School of Public and Population Health	09/2013		Supervisor
Pardis Lakzadeh, BSc ²	M.Sc., School of Public and Population Health	06/2013		Supervisor
Zack Daly, BSc	M.Sc., Faculty of Land and Food Systems	09/2012		Committee Member
Samantha Pollard, MSc	Ph.D., Population and Public Health	09/2012		Committee Member
Kyly Whitfield, MSc	Ph.D., Faculty of Food and Nutrition Sciences	09/2012		Committee Member

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Wenjia Chen, MSc	Ph.D., Faculty of Pharmaceutical Sciences	05/2014		Co-Supervisor
Zafar Zafari, MSc	Ph.D., Faculty of Pharmaceutical Sciences	05/2012		Committee Member
Natalie McCormick, MSc	Ph.D., Faculty of Pharmaceutical Sciences	09/2012		Committee Member
Elizabeth Wilcox, MA	Ph.D., Population and Public Health	09/2012		Co-Supervisor
Alberto Mendoza-Galina, BSc	M.A., School of Journalism	09/2011	10/2013	Co-Supervisor
Keith Rozendal, PhD ³	M.A., School of Journalism	09/2011	10/2013	Co-Supervisor
Adam Raymakers, MA	Ph.D., Faculty of Pharmaceutical Sciences	09/2011		Supervisor
Shirin Rizzardo, BSc(Pharm) ⁴	M.Sc., Faculty of Pharmaceutical Sciences	09/2011	04/2014	Supervisor
Mehran Najibnia, BSc(Pharm)	M.Sc., Faculty of Pharmaceutical Sciences	09/2011	On leave	Committee Member
Kirby Smith	M.Sc., Faculty of Pharmaceutical Sciences	09/2012		Supervisor
Ryan Maltais, BSc (Pharm)	M.Sc., Faculty of Pharmaceutical Sciences	01/2011	Withdrew 01/2013	Committee Member
Negar Omid, BSc	M.Sc., Faculty of Land and Food Systems	09/2010	11/2012	Committee Member
Natalie McCormick, BSc	M.Sc., Faculty of Pharmaceutical Sciences	09/2009	06/2012	Committee Member
Lilla Roy, BSN	M.Sc, Faculty of Pharmaceutical Sciences	09/2010	09/2013	Supervisor
I Fan Kuo, PharmD ⁵	M.Sc. Faculty of Pharmaceutical Sciences	09/2010	04/2014	Supervisor
Mohsen Sadatsafavi, MD ⁶	Ph.D., Faculty of Pharmaceutical Sciences	09/2008	01/2012	Committee Member
Bridgette Oteng, BA	M.Sc., Faculty of Pharmaceutical Sciences	09/2007	11/2009	Committee Member
Katie Sweeney, BSc	M.Sc. Faculty of Pharmaceutical Sciences	09/2007	09/2010	Supervisor
Belinda Chen, BSc	M.Sc., Faculty of Pharmaceutical Sciences	09/2007	11/2010	Supervisor
Mehdi Najafzadeh, MA	Ph.D., Faculty of Pharmaceutical	09/2007	02/2012	Committee Member

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
	Sciences			
Vivian Leung, PharmD	Ph.D., Faculty of Pharmaceutical Sciences	09/07	09/2012	Committee Member
Camilla Guimaraes, MSc ⁷	Ph.D., Faculty of Pharmaceutical Sciences, University of Sal Paulo, Brazil	09/2005	04/2009	Co-supervisor (Primary Canadian Supervisor)
Kelly Grindrod, PharmD ⁸	M.Sc, Faculty Pharmaceutical Sciences	05/2007	11/2009	Co-Supervisor
John Woolcott, MA ²	Ph.D. Faculty of Pharmaceutical Sciences	09/2005	05/2012	Committee Member
Helen McTaggart-Cowan ⁹	M.Sc., School of Population and Public Health	09/04	09/06	Co-Supervisor
Pauline Leung	Ph.D.	01/07	w/d for health reasons 06/07	Co-Supervisor

¹Master training scholarship – CIDA/UWO/NUR/CIDA Maternal, Newborn, and Child Health Training Program

²Pfizer Studentship – Health Outcomes Research

³CIHR Graduate Fellowship

⁴Pharmaceutical Policy Research Collaboration Fellowship and Merck Canada Postgraduate Fellowship

⁵recipient of Heart and Stroke Foundation of Canada/CIHR postdoctoral fellowship

⁶recipient of a CIHR Banting and Best Doctoral Award and MSFHR Senior Trainee Award

⁷Graduate exchange student from Brazil. Completed all course work in Brazil, received scholarship to undertake research component of degree abroad. Sought out my research program to undertake her research project, under my supervision. Completed her PhD dissertation under my sole supervision in Canada.

⁸Michael Smith Foundation for Health Research doctoral award and a CIHR doctoral award

⁹Michael Smith Foundation for Health Research trainee award

¹⁰recipient of a CIHR Frederick Banting and Charles Best Graduate Scholarship

Post-doctoral Fellows Supervised

Fellow Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Nick Dragojlovic, PhD ¹	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	09/2013		Supervisor
Conor Douglas, PhD	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	07/2013		Supervisor
Pierrick Bedouch, PhD ²	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	08/2010	08/2011	Supervisor
Nick Bansback, PhD ³	Postdoctoral Fellow, School of Pop. and Public Health	01/2010	01/2011	Co-Supervisor

¹CIHR/Pfizer Post-doctoral Fellowship for Rare Diseases, Michael Smith Foundation for Health Research (MSFHR) Post-Doctoral Fellow Trainee Award

²Sanofi-Aventis award and funding from Grenoble University Hospital

³Canadian Arthritis Network Postdoctoral Fellowship

Graduated Student/PDF Supervised: Current Positions

Shirin Rizzardo, MSc – Pharmacist, Medical Beneficiary & Pharmaceutical Services Division, BC Ministry of Health

I fan Kuo, PharmD, MSc – Assistant Professor, School of Pharmacy, Faculty of Health Sciences, University of Manitoba

Lilla Roy, MSc – Clinical Research Project Coordinator, Hospital for Sick Children, Toronto

Belinda Chen, MSc – Research Assistant, BC Neuropsychiatry Program, Vancouver Coastal Health

Nick Bansback, PhD - Assistant Professor, School of Population and Public Health, UBC

Pierrick Bedouch, PhD – Head, Clinical Pharmacy Unit – Pharmacy Department, Grenoble University Hospital, Grenoble, France

Kelly Grindrod, Pharm.D, MSc – Assistant Professor, School of Pharmacy, University of Waterloo

Camila Guimaraes, PhD - Professor, Department of Clinical, Toxicological and Bromatological Analysis, University of São Paulo, Brazil

Helen McTaggart-Cowan, PhD – Health Economist, BC Cancer Agency

Graduate Student Supervisory Committees Chair/ Examinations

Student Name	Program Type	Date	Role
Jailin Xu	M.Sc.	2012 - present	Thesis Committee Chair
Jayakumar Surendraddoss	M.Sc.	2008 - 2012	Thesis Committee Chair
Marion Pearson	M.Sc.	09/08	University examiner – thesis defense
Alexis Twiddy	M.Sc.	2009 - 2013	Thesis committee chair
Samantha Bowker	Ph.D. (U of A)	11/07	External examiner – comprehensive exam
Magnolia Pak	Ph.D.	09/07 - 2012	Thesis Committee Chair
Karen Long	M.Sc.	09/04 - 08/06	Thesis Committee Chair
Jennifer Rose St. Onge	Ph.D.	12/2011	Thesis Committee Chair, Oral Exam Chair

Pharm.D. Students Supervised

Student Name	Date	Project
Melanie Sunderland	03/2014	Newborn screening for tyrosinemia
Queeny Ip (U of Arizona)	5/2012	Drug prices for expensive drugs for rare diseases
Arden Barry	5/2009	PharmD Rotation
Ruth Tsang*	03/2007	Type II error in adverse event analysis in randomized controlled trials (published)
Sean Spina	02/2007	Utilities and quality of life in Irritable Bowel Syndrome
Adil Virani	03/1997	Quinine-induced thrombocytopenia
Christine Hughes	02/1997	Venlafaxine related hypertension
Wendy Gordon	01/ 1997	Low molecular weight heparin-induced thrombocytopenia
Patricia Gerber*	12/1996	SSRI-Induce dystonic reactions (published)
David Gardner*	11/1996	Sumatriptan and the risk of serotonin syndrome (published)
Ema Ferreira	10/1996	Risk of thromboembolism related to 3 rd generation progestins
Allan Low	10/1995	Drug information rotation
Suzanne Malfair	04/1995	Drug information rotation
Carlo Marra*	03/1995	Drug information and toxicology resources on the Internet (Published)
Donna Buna	02/1995	Drug information rotation
John Forrester-Coulle	11/1994	Drug information rotation
John Mcready	10/1994	Drug information rotation
Linda Sulz	05/1995	Drug information rotation
Brenda Johannesson	03/1994	Drug information rotation
Margaret Ackman	02/1994	Drug information rotation
Jane Delemos	01/1994	Drug information rotation

Fawziah Lalji	10/1993	Drug information rotation
Shallen Letwin	01/1993	Drug information rotation

* = published a paper during rotation under my supervision

Undergraduate Summer (SSRP), Directed Studies (DS) Students, Research Assistants (RA) Supervised

Student Name	Program Type	Year		Principal Supervisor	Co-Supervisor(s)
		Start	Finish		
Michelle Lee	SSRP	June/2013	Aug/2013	Larry Lynd	
Justin Sciani	RA	May/2012	Aug/2012	Larry Lynd	
Alana Isakovic	RA	July/2009	present	Larry Lynd	Carlo Marra
Alicia Lin	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Omid Zargaran	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Ahmad Abouzant	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Diana Lam	RA	July/2009	Oct/2009	Larry Lynd	Carlo Marra
Allan Lee	DS	Sept, 2007	Apr, 2008	Larry Lynd	Carlo Marra
Wendy Li	SSRP	June, 2007	Aug, 2007	Larry Lynd	Carlo Marra
Eric Poulin	SSRP	May, 2005	Aug, 2005	Larry Lynd	Carlo Marra
Victorine Ssozi	DS	May, 2005	Aug, 2005	Larry Lynd	Carlo Marra
Jackie Siu	DS	May, 2005	Aug, 2005	Carlo Marra	Larry Lynd

(d) *Continuing Education Activities*

Course	Institution/Location	Date
Modeling decision making and discrete choice behaviour	Statistical Innovations, Boston, MA	Oct. 21 - 22, 2010
Certificate in Teaching and Learning in Higher Education	University of British Columbia, Vancouver, BC	2005 - 2006
Using discrete choice experiments in health economics	University of Calgary, University of Aberdeen. Lake Louise, AB	Sept. 29 - Oct. 1, 2004
Using Bayesian methods for cost effectiveness analysis	Society for Medical Decision Making Short Course. Chicago, IL.	Oct. 19, 2003
Reducing Bias in observational studies: Propensity Methods	Society for Medical Decision Making Short Course. Chicago, IL.	Oct. 19, 2003
Advance modeling methods for economic evaluation	Centre for Health Economics, York and Oxford Universities. Oxford, UK	Sept. 2003
HRM 737-Economic analysis for the evaluation of health services	Faculty of Health Sciences, McMaster University, Hamilton, ON	Jan. - Apr. 2003
Designing and Implementing Economic Evaluations of Medicines	Centre for Evaluations of Medicines, McMaster University, Hamilton, ON	2003
Advanced methods in economic evaluation	Centre for Evaluation of Medicines / McMaster University, Hamilton, ON	2003

(e) *Other*

Activity	Institution/Company	Dates
----------	---------------------	-------

Instructor – BC Pharmacy Residents, Evidence Based Medicine Rotation	BC Interior Health Authority	July 14, 2014
Instructor – Hospital Pharmacy Residents	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1990 - 1997
Coordinator – Hospital Pharmacy Residents Drug and Poison Information rotation	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1992 - 1994
Instructor – PharmD students Drug Information	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1994 - 1997
Coordinator – PharmD students Drug Information and Toxicology rotation	BC Drug and Poison Information Centre/Faculty of Pharmaceutical Sciences, UBC	1995 - 1997

9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

Since joining the University of British Columbia as a tenure track assistant professor, I have been the **Associate Director of the Collaboration of Outcomes Research and Evaluation (CORE) – website: www.core.ubc.ca**. The mission of CORE is to improve health-related outcomes to drug therapy through the application of the best in research, education, and practice enhancement strategies. This involves collaboration with other outcomes researchers, professional organizations, and policy makers. However, prior to 2004, CORE did not have any formal funding, trainees, or formalized structure. In collaboration with Dr. Carlo Marra who joined the faculty at the same time, our mandate has been to develop CORE in terms of both research and training in pharmaceutical outcomes. In this regard, over the past four years we have accrued more than \$2 million in research funding, hired a core group of epidemiologists, health economists, and statisticians, recruited numerous graduate students, and acquired the computer resources to undertake sophisticated modeling and analysis. We have also established collaborative associations with other key stakeholders including the BC College of Pharmacists, BC Pharmacy Association, BC Ministry of Health, and BC Pharmacare and collaborate both nationally and internationally. In terms of training, in addition to training graduate students in outcomes research, we have developed the first undergraduate course in pharmacoconomics and health technology assessment with the objective of training clinicians in critical thinking, understanding health care and policy decision making, and incorporating evidence into clinical practice.

(a) *Areas of special interest and accomplishments*

My primary areas of scholarly interest in the conduct of state of the art outcomes research and epidemiologic studies including cost-effectiveness analysis and therapeutic risk benefit analysis using state-of-the-art computer simulation modeling techniques (including decision analysis, discrete event simulation, Monte Carlo simulation, Markov modeling), measurement of health related quality of life and patient's preferences, and pharmacoepidemiology. One of my primary research objectives is to be involved specifically in research that will ultimately translate into improved patient outcomes, or be integrated into the decision-making process.

One of my primary disease areas of interest is in respiratory diseases, specifically asthma and COPD. Because the evaluation of health outcomes has no geographic or disease-specific boundaries, I have also become involved in a number of international studies that have the potential to influence policy in these countries.

Finally, through my involvement in the BC Ministry of Health Expensive Drug for Rare Diseases advisory committee, to which I was appointed for a second term for my health economics expertise, I have identified significant knowledge gaps relating to policy and decision-making association with orphan drugs, and expensive drugs for rare diseases. As such, I was successful in receiving a CIHR team grant, as the PI, for a national, multi-disciplinary team of economics, epidemiologists, policy research, ethicists, lawyers, clinicians, and knowledge users, to develop new knowledge relating to funding and reimbursement of expensive drugs for rare diseases.

1. Funding and Reimbursement for Orphan Drugs (www.rare-diseases.ca)

Given the significant knowledge gap in this area, particularly in Canada, and my development of specific research questions in this area, I took the lead on developing a Canadian team of internationally recognized leaders in economics, health policy, epidemiology, health ethics and law, and clinical genetics, as well as key stakeholders and knowledge users. Working with this group, we identified a number of key questions that needed to be addressed, and I lead the development and submission of a team grant. Our LOI was one of 12 successful LOIs out of more than 90 LOIs submitted. In the granting process, we were ranked 2nd (score 4.56) out of 12, with the top application scoring 4.61, and we were one of 4 groups funded in the health policy arena. The total funding for this project is \$1.47 million over 5 years. While I am overseeing all projects in multiple research areas as the PI on this project, my specific area of interest is the evaluation of societal values and willingness to pay for expensive drugs for rare diseases. In this regard, I have one existing graduate, and 3 new graduates working in this area.

i. Canadian societal views on reimbursement of high-cost medications for rare diseases

As part of the team grant, I have completed data collection (August, 2013) on a project to generate empirical evidence on what the values and priorities of the public as a stakeholder are (MSc project – Shirin Rizzardo). The aim of this project is to determine whether rare conditions are an area of drug-reimbursement for which value-based funding should be made, and whether there is rationale for them to be exempt from traditional cost-effectiveness thresholds. Secondly, this information will be of value to decision-makers who should strive to represent society's best interests. In the UK citizens' council half of the council felt that premium prices should be paid for rare disease treatment, with certain conditions being met such as disease severity and treatment gain. Information such as this can guide policy change. The decision-makers will be informed as to what the Canadian public value when making medication-reimbursement decisions, whether orphan drugs should undergo value-based decisions, and finally what these values should be. We aim to determine: 1) which factors, priorities and values the Canadian public feel should be used in pharmaceutical-reimbursement decisions; 2) whether rarity is valued by society; 3) if society is willing to accept the opportunity costs associated with funding a rare disease; 4) what is the maximum amount the Canadian public feels should be spent on a pharmaceutical health-care intervention; and 5) if they would support paying higher taxes in order to accommodate the costs of expensive medications.

ii. Using scenario studies to inform reimbursement decision-making for orphan drugs

In light of the policy challenges surrounding orphan drug coverage we have designed a multi-method research study that directly partners with and engages the decision-makers in this area. We aim to equip decision-makers with tools to ensure sustainable access to medicines for a diversity of patient populations, given that orphan drugs for rare diseases rarely meet the usual thresholds for cost-effectiveness. We propose to use scenarios in a focus group setting with orphan drug coverage decision-makers in four provinces across Canada (whom have already expressed interest in participating as Knowledge Users) to collectively explore how their adjudication processes will address future challenges. A scenario study is a specific methodology of Constructive Technology Assessment (CTA); however, instead of simply looking at the *current* state of a technology, researchers use scenarios in the form of stories, narratives, or news items of the future to engage stakeholders in thinking about how current technological and social contexts will unfold and influence the trajectory of a technology such as orphan drugs.

2. International Health – Rwanda and Cambodia

i. The Muskoka Initiative Partnership Project – Maternal, Child, and Newborn Health

Having been involved in a previous project in Rwanda where I was responsible for the development of the analytic plan and all data analysis, I became involved in a follow-up project to implement some of the recommendations from the initial project, an Evaluation of Health Care Quality in Rwanda. In this second project, I am a co-investigator on a \$1.8M, 3 year project, funded by the Canadian International Development Agency, to implement specific programs in Rwanda aimed at improving maternal and child health outcomes. As the outcomes researcher on the project, I am working with Rwandan partners/collaborators to develop methods for the evaluation of our project and the ongoing evaluation of maternal and child outcomes in Rwanda. Through a competitive process involving a request for application from Rwandans, I recruited a Rwandan graduate student (Dr. Celestin Hantegakimana), a Rwandan-trained physician, who is enrolled in the School of Population and Public Health (UBC) and will complete the outcomes evaluation of this project as his MSc thesis.

ii. Nutritional “Sprinkles” implementation in Rwanda

In collaboration with Dr. Judy McLean from Family and Nutrition Health at UBC, I am involved in an evaluation of the implementation of micronutrient “Sprinkles” in Rwanda. We are initially involved in deployment of the Sprinkle program in select districts as a pilot study to facilitate evaluation. Based on the results and outcomes of the evaluation, the information will be provided to the Rwanda Ministry of Health to support the decision on whether to roll the program out in the entire country. This pilot study is now complete, and additional funds have been acquired from Unicef to support country-wide implementation.

iii. Integration of small-scale aquaculture with homestead food production for improved household food security and nutrition in rural Cambodia – “Fish on Farms” (www.fishonfarms.landfood.ubc.ca)

The Fish on Farms project is being jointly conducted by the University of British Columbia (UBC) and Helen Keller International (HKI), with technical assistance from World Fish, in Prey Veng Province, Cambodia. This project, supported by a \$2.9M grant from IDRC and CIDA through the Canadian International Food Security Research Fund (CIFSRF), is studying how an integrated Homestead Food Production system will impact poverty, food security, and nutrition, particularly among women and children. This will be the first project to rigorously measure the effectiveness of different models of Homestead Food Production at reducing under-nutrition using biochemical and anthropometric measurements.

As a co-investigator on this grant, I am responsible for the development of the outcomes evaluation and analysis plan, the final analysis, as well as an economic evaluation of the program to facilitate the evaluation of long term sustainability of the program. The results of this analysis will be communicated to our Cambodian government partners such that they will help inform future resource allocation and program development decisions throughout the country. I recruited a new graduate student (Pardis Lakzadeh) enrolled in the School of Population and Public Health (UBC) who will complete the economic evaluation as her MSc thesis.

3. Developing methods for quantitative risk benefit analysis.

This is one of my primary areas of research interest and as such, has been one area where I have developed an international recognition. The area of research is multi-factorial that encompasses the integration of epidemiologic and pharmacoepidemiologic methods with methods grounded in health economics and as such, my training and expertise in both areas has been a significant asset. As part of this unique line of research, I received grants from the Canadian Foundation for Innovation and BC Knowledge Development Fund to establish the Laboratory for Therapeutic Risk Benefit Assessment. As such, this research area has spawned a number of projects in a number of disease areas. As part of this area of research, I have published a conceptual, methodologic paper illustrating the limitations and frequency of using standard frequentist statistics to evaluate adverse event rates in randomized controlled, and the erroneous use of these results to make risk-benefit decisions (Journal of Clinical Epidemiology 2008). This paper supports the use of non-frequentist statistics and probabilistic computer simulation models to undertake risk-benefit analysis. As one of the foundations for this area of research is the concept of decision-maker’s preferences, a number of recent projects have involved the elicitation of preferences, both societal and patients, for health interventions or outcomes.

i. Stroke prophylaxis

Antithrombotics remain the cornerstone of stroke prevention in patients with atrial fibrillation (AF). Aspirin (ASA) for patients at low risk of stroke and Vitamin K antagonists (VKA) such as warfarin for patients at moderate-to-high risk have been considered the treatments of choice for the past decades. While evidence suggests that both agents can reduce the annual risk of stroke, use of either agent is associated with increased bleeding rates, especially with VKA therapy. The risk for bleeding in addition to the requirement for regular laboratory monitoring in patients receiving VKA had therefore prompted the recent discovery of novel antithrombotic regimens such as direct thrombin inhibitors (eg. dabigatran), indirect Xa inhibitors (eg. rivaroxaban) and combination therapy of clopidogrel and ASA. The emergence of these new therapies, however, poses a challenging dilemma for decision makers at the regulatory, policy-making and clinical levels in terms of attempting to determine which treatment strategy provides the greatest benefit with least risk, while considering patients' preferences for the outcomes. Thus, I am currently involved in study (Dr. Ifan Kuo – MSc project) to determine the risk preferences of patients with atrial fibrillation, after which we will incorporate these preferences weights into a quantitative benefit-risk model that will hopefully inform treatment decisions and policy and guideline development.

ii. Isoniazid for treatment of latent TB

Despite the substantial impact of policies and guidelines aimed at reducing INH-induced hepatotoxicity, questions remain concerning the tradeoffs between the potential benefits and risks of treatment of LTBI patients with INH. This trade-off is further complicated by the differences in the risk of developing active TB. By implementing quantitative benefit-risk analysis methods that I have used previously, we adapted a previously developed cost-effectiveness analysis model to undertake a quantitative benefit-risk analysis of INH for the treatment of LTBI in hypothetical cohorts of TB contacts defined by several risk factors for progression to active TB which can be easily elicited at the time of screening. Using the incremental net quality-adjusted life years (QALY) framework (13), the potential risks and benefits are combined into a common metric (QALY) such that a positive incremental net QALY favors INH treatment whereas a negative value favors no treatment. The results of this analysis are currently *in press* in Value in Health.

iii. Rheumatoid arthritis

As part of an empiric evaluation of using the incremental net benefit framework and computer simulation modeling for risk benefit analysis, I lead the development of a quantitative risk benefit analysis model to quantitatively evaluate the risks and benefit of rofecoxib relatively to naproxen in rheumatoid arthritis. This study was of significant interest to regulatory decision makers at the US Food and Drugs Administration (FDA) and the European Medicine Agency (EMA) as a result of podium presentations at a number of international conferences (International Society of Pharmacoepidemiology, Society of Medical Decision Making, International Society for Pharmacoeconomics and Outcomes Research) and the results that showed the benefits outweigh the potential risks (published in Pharmacoepidemiology and Drug Safety). This has resulted in invited presentations to the US Pharmaceutical Manufacturers Association, the US FDA, and the EMA, and an appointment to the Next Steps Working Group of the US FDA for quantitative risk benefit analysis. Given that the previous study was done from the perspective of society, I have completed a follow-up study to evaluate patients' preference for potential risks and benefits of oral drug therapies for RA (Belinda Chen – MSc thesis project); the manuscript of the results of this project is currently in the final stages. Given my involvement in the Next Steps working group, these two studies will serve to inform regulatory decision-makers on the ability to objectively incorporate patients' preferences into the decision-making framework.

iv. Inflammatory Bowel Disease

This project was funded by a Grant-in-Aid from GlaxoSmithKline, and manufacturer of alosetron which was pulled from the US market due to safety concerns, and then reintroduced. The results of this study are currently under review in Medical Care. This study has also been presented a numerous international meetings and has drawn the attention of the US FDA from the perspective of how this analysis could have been used to inform their decision making. As such, the results of this analysis have been presented to both the US FDA and EMA, the result of which have been published in publications in Value in Health.

4. Examination of Patient and Societal preferences for health states.

A large part of my research program is devoted to investigating health economic issues in chronic diseases from the perspective of both risk-benefit and cost-effectiveness analysis. Specifically, demonstrating cost-effectiveness has emerged as an additional hurdle for drugs and technologies to get past in order to be approved or funded by third-party payers. As such, there is a necessity for methodological rigor in all aspects of the evaluations including the measurement of effectiveness. One of the most common measures of benefit utilized is the quality adjusted life year (QALY) which is derived from both the length of time spent in a particular health state and society's valuation of that health state. My group does research to examine the validity of different health state systems and valuation techniques. As a result of my expertise in this area as well as health economics and epidemiology, I have been appointed to the Expensive Drugs for Rare Diseases committee, an advisory committee to the Pharmaceutical Services Division of the BC Ministry of Health Services.

i. Respiratory Syncytial Virus (RSV)

The prevalence of RSV in children is extremely high, infecting approximately 70% of infants under one year. It is also the leading cause of bronchiolitis hospitalizations in infants. Informed clinical decisions require a measure of the impact of RSV on an infant's quality of life; however, determining health utility values for infants is challenging. Infants cannot communicate their preferences, and so we must rely on proxies to elicit health utilities. Proxies risk interaction between the proxy's utility and that of the child's, and also it does not give the standard representative "societal" perspective. There is currently no established standard for eliciting health utilities for children. The temporary nature of RSV means that the impact on a Quality Adjusted Life Years (QALYs) is likely to be low; however, RSV has potential long-term impacts on health such as asthma and wheeze. Thus, in a study funded by Abbott, I have just completed a project in which we explore the methodology surrounding deriving health utilities from infants, in temporary health states, and ultimately the derivation of health utilities for infants (Ms. Lilla Roy, MSc thesis project). This in turn should contribute to the evaluation and reimbursement decisions relating to treatments for RSV.

iii. Interventions For Moderate/Severe Obstructive Sleep Apnea/Hypopnea

Obstructive sleep apnea/hypopnea is a major public health concern. This condition has a high prevalence and those who suffer from it are at a higher risk of motor vehicle crashes and probably have a higher incidence of cardiovascular conditions than the general population. Using stated-choice methods, we are currently investigating patients' preferences for different attributes of treatment associated with the use of dental appliances or continuous positive airway pressure (CPAP). This research is done in collaboration with researchers within the *Michael Smith Foundation for Health Research Respiratory Sleep Disorders Research Unit*.

5. Respiratory Medicine

As part of the BC Lung funded project to evaluate patients' preferences for treatment related risks and benefits in asthma, we undertook an evaluation of generic, preference based quality of life instruments in asthma. The result of this study have been presented at a number of international respiratory and outcomes conferences, and has been published in *Quality of Life Research* (2008) as part of Dr. McTaggart-Cowan's MSc thesis. The results of this cross-sectional study call into question the discriminative validity of these instruments in asthma, which has significant implication for their use to determine quality adjusted life years for cost-effectiveness in asthma. Specifically, these instruments may not detect clinically important change in asthma, and as such, no asthma treatment will appear to be cost-effective. This may result in asthma drugs not being covered by insurance companies limiting patient access. I am therefore in the planning stages of a follow-up longitudinal study of these instruments in asthma.

In this regard, I am a co-investigator on a \$1 million grant (\$200k per year for 5 years) for a Respiratory Evaluation Sciences Program from the National Sanitarium Association to examine health economic issues in respiratory illnesses. Part of this work will be to investigate patient and societal preferences for health states in respiratory diseases including asthma, COPD, pulmonary hypertension and tuberculosis. This work will build on projects that we have previously completed previously as discussed above.

i. Platform for Outcomes Research in Allergy and Asthma (PORTAL)

I am the co-PI on a multi-year, multi-institutional grant to undertake outcomes research and evaluation, funded by the AllerGen NCE, related to asthma and allergy. While we were initially funded for \$300,000 over 3 years, we have just recently been granted a 4 year, \$150,000 initial renewal, with opportunities for additional funding over the upcoming 4 years. Under the this grant, we have completed an evaluation of the Economic Burden of Asthma in BC (published in the Canadian Respiratory Journal), and we currently have a number of additional publications related to this analysis under review. I am also currently involved in a project aimed at integrating these results into a population-based burden of disease simulation model that will allow us to evaluate the implementation of the asthma-related interventions.

Stemming from my dissertation research that focused on asthma management strategies and social class differences in asthma management, the findings of which resulted in four manuscripts in the Canadian Medical Association Journal (2001), European Journal of Epidemiology (2004), and Chest (2002 and 2004). Further to this, I have been actively involved in additional studies evaluating outcomes in asthma, specifically related to antibiotics in the first year of life and the risk of asthma, funded by the BC Lung Association, which has resulted in two manuscripts in Pediatrics (2008) and Chest (2006). Specific to COPD, I have just received a CIHR operation grant to evaluate the association between inhaled corticosteroids and the subsequent development of lung cancer using administrative health data in BC. The establishment of this cohort for this study will facilitate further COPD-specific outcomes related studies.

ii. The association between inhaled corticosteroids, statins, and lung cancer in COPD

I am leading a CIHR-funded pharmacoepidemiology study to evaluate the potential protective effect of inhaled corticosteroids and statins in the development of lung cancer in patients with COPD. This study is based on the richest and most robust population-based dataset available anywhere, including prescription drug use, hospitalizations, physician visits, and cancer registry/diagnostic data. Although this study was funded in 2008, there was a significant delay in receiving the data from the BC Ministry of Health such that the data were only received late in 2011. This project will form the basis of Adam Raymakers PhD dissertation.

6. Pharmacy Practice Research

i. Pharmacist prescribing and provision of chronic disease management.

As background to two ongoing projects, I have authored two papers addressing the issue of pharmacists' prescriptive authority in Canada in the two primary Canadian pharmaceutical practice and medicine journals (Canadian Medical Association Journal 2005, Canadian Pharmaceutical Journal 2004). In a Canadian Foundation for Pharmacy funded project, we evaluated the question if pharmacists prefer the provision of care for chronic diseases to traditional dispensary functions.

We also completed a project working with the Pharmacy Associations of both Alberta (where the provision of chronic disease management, namely hypertension, is being discussed by provincial government and professional bodies) and British Columbia. The focus group component of this project resulted in two manuscripts (Can Pharm J) which formed the basis for the quantitative component of the study which has been published in the Annals of Pharmacotherapy. Dr. Kelly Grindrod's MSc thesis was based on this project. The results of this project were used by the BC Ministry of Health and the BC Pharmacy Association to help inform the negotiations relating to pharmacist reimbursement for professional services.

In tandem with this project, I am the lead investigator of a CIHR-funded study (ranked #1) to evaluate patients' preferences for pharmacist provision of chronic disease management using a discrete choice experiment. As this project has just been funded, we are in the process of initiating the focus group component of the study. These two studies are expected to contribute significantly to the future developments in the shifting paradigm of chronic disease management in Canada.

Finally, in collaboration with Dr. Carlo Marra, we are currently undertaking an evaluation of the Medication Management Program in British Columbia, once again funded by the BC Pharmacy Association, in collaboration with BC Ministry of Health.

(b) Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))

Granting Agency	Subject	COMP	\$ Per Year (Total)	Year	Principal Investigator	Co-Investigator(s)
Canada Foundation for Innovation	CFI Infrastructure Operating Fund		\$37,095	2014 – 2019	Dr. L.D. Lynd	
CIHR-MSFHR Partnerships for Health System Improvement	Informing Future Orphan Drug Coverage with Scenario Studies (iFOCUSS)	C	\$117,900 (\$235,801)	2014 – 2016	Co-PIs Dr. L.D. Lynd and Dr. T. Clifford	Dr. C. Douglas
College of Pharmacists of British Columbia	EmPhAsIS: Empowering pharmacists in asthma management through interactive SMS	NC	\$250,000	2014 – 2018	Dr. M. De Vera	Dr. C. Marra Dr. L. Lynd Dr. M. Sadatsafavi
AstraZeneca Canada	Evaluating pharmacist prescribing of single inhaler therapy in uncontrolled asthma – A pilot study	NC	\$59,931	2014 – 2015	Dr. L.D. Lynd	
UBC Faculty of Pharmaceutical Sciences Research Innovation Fund	Collaborative, Coordinated, Research, and Evidence-Based Medication Adherence Platform (CoREMAP)		\$4,000	2014	Dr. M. De Vera	Dr. C.A. Marra Dr. L. Lynd
Canadian Foundation for Innovation	Outcomes research in community pharmacy practice: Innovation using eHealth	C	\$38,463	2014	Dr. L.D. Lynd	Dr. C.A. Marra Dr. P. Zed
IDRC	Integration of Small-Scale Aquaculture with Homestead Food Production for Improved Household Food Security and Nutrition in Rural Cambodia	NC	\$32,164	2013 – 2015	Dr. L.D. Lynd	
CIDA/Univ of Western Ontario	Maternal, Newborn & Child Health in Rwanda	NC	\$42,289	2013 – 2015	Dr. L.D. Lynd	

Canadian Institutes of Health Research	COPD as a systemic disease: Mapping the clinical research agenda to improve patient and societal outcomes	C	\$23,156	2013 – 2014	Dr. Mohsen Sadatsafavi	Dr. J. Avina-Zubieta Dr. S. Bryan Dr. J. FitzGerald Dr. W. Leslie Dr. L. Lynd Dr. G. Mancini Dr. C. Marra Dr. D. Sin Dr. W. Tan Dr. S. Viran
Canadian Foundation for Pharmacy	PhinDMORE: Pharmacist Innovative Drug Therapy Management Outcomes, Resource use and Economics	C	\$35,000	2013	Dr. Carlo Marra	Dr. Larry Lynd John Shaske
Irish Aid and Unicef Zambia	MNP Pilot Study for the Development of a Home Fortification Programme for Young Children in Zambia	C	\$198,000 <i>US total</i>	2012 – 2014	Dr. Judy McLean (Co-PI) Dr. Larry Lynd (Co-PI)	
Unicef Cameroon	Formative Research for Development of a Home Fortification Program for Young Children in Cameroon	C	\$87,000 US	2013	Dr. Judy McLean (Co-PI) Dr. Larry Lynd (Co-PI)	
Unicef Rwanda	The Implementation of In-Home Fortification and Nutrition Education to Combat Anaemia and Micronutrient Deficiencies among Children 6-23 months in Rwanda	C	\$76,000		Dr. Judy McLean (Co-PI) Dr. Larry Lynd (Co-PI)	
Canadian Institutes of Health Research	Improving adherence to treatments through behavioural economics: Testing an enhanced decision aid in patients with obstructive sleep apnea	C	\$100,000	2013	Dr. Nicholas Bansback	Dr. F. Almeida Dr. N. Ayas Dr. P. Brasher Dr. L. Lynd Dr. C. Marra Dr. D. Stacey
AllerGen NCE	Platform for Outcomes Research and Translation in Asthma and aLlergy (PORTAL) – Renewal	C	\$37,500 (\$150,000)	2012 - 2016	Dr. L.D. Lynd	Dr. W. Unger Dr. C. Marra Dr. S. Dell Dr. S. Elliott Dr. A. Clarke Dr. J.M. FitzGerald

International Development Research Centre	Integration of small-scale aquaculture with Homestead Food Production for improved household food security and nutrition in rural Cambodia	C	\$967,000 (\$2.9M)	2012 - 2014	Dr. Tim Green	Dr. J. McLean Dr. L. Lynd Dr. A. Talukder
Canadian Institutes of Health Research	Developing a Canadian Framework for Evaluation and Decision-Making for Expensive Drugs for Rare Diseases Through Innovation, Value, and Priority Setting	C	\$324,542 (\$1.47M)	2012 - 2017	Dr. L.D. Lynd	Dr. S. Bryan Dr. L. Clarke Dr. T. Clifford Dr. D. Coyle Dr. J. Friedman Dr. Y. Joly Dr. B. Jones Dr. P. Klein Dr. B. Knoppers Dr. E. Lun Dr. C. Marra Dr. F. Miller Dr. C. Mitton R. Nakagawa Dr. V. Ozdemir Dr. S. Sirrs
Canadian Institute of Health Research	Planning Meeting for Developing a Canadian Framework for Reimbursement Decision-Making for Expensive Drugs for Rare Diseases	C	\$24,666	2012	Dr. L.D. Lynd	+ 16 others
Canadian International Development Agency	Muskoka Initiative Partnership Program for Maternal, Newborn, and Child Health in Rwanda	C	\$600,000 (\$1.8 M)	2011 - 2014	Dr. David Cechetto	Dr. L. Lynd + 10 others
BC Pharmacy Association	BC Medication Management Project (BCMMP) Qualitative Evaluation		(\$263,000)	2012 - 2013	Dr. Carlo Marra	Dr. L. Lynd
Canadian Institute for Health Research	The impact of price-caps on the generic pharmaceutical industry and provincial drug plan costs in Canada	C	\$55,892	2012 - 2014	Dr. Aslam Anis (Co-PI) Dr. Carlo Marra (Co-PI)	Dr. L. Lynd Dr. B. Wilmer
Canadian Institute for Health Research	Understanding persistent antipsychotic polypharmacy: a prevalent practice without evidence	C	\$238,516	2010 - 2013	Dr. Ric Procychn (Co-PI) Dr. Alasdair Barr (Co-PI)	Dr. W. Honer Dr. J. Johnson Dr. L. Lynd

Canadian Institute for Health Research	A randomized controlled trial evaluation of brief, telephone supported CBT self-help in primary care patients with mild to moderate depression	C	\$182,977	2010 – 2013	Dr. Mark Lau	Dr. S. Hollon Dr. L. Lynd
Canadian Institute for Health Research	The Feasibility of Using Community Pharmacists in Focused Surveillance for Drug Safety and Effectiveness: A Case Study of Anti-Hypertensives in Pregnancy	C	\$98,847	2010 - 2011	Dr. Larry Lynd (Co-Principal Investigator) Dr. Carlo Marra (Co-PI)	Dr. E. Ferreira Dr. L. Magee Dr. P. Von Dadelnszen
Canadian Institute for Health Research	Effects of Prescription Adaptation and Renewal by Pharmacists	C	\$309,472	2010 - 2013	Dr. Michael R. Law	Dr. Larry Lynd Dr. SR Majumdar Dr. Carlo Marra Dr. Steven Morgan
AllerGen NCE	Platform for Outcomes Research and Translation in Asthma and aLlergy (PORTAL)	C	\$100,000 (\$300,000)	2009 – 2012	Dr. Larry Lynd	Dr. Wendy Ungar Dr. Carlo Marra Dr. Sharon Dell Dr. Susan Elliott Dr. Anne Clarke Dr. J.M. FitzGerald
AllerGen NCE	Consumer Preferences for Allergen Food Labeling	C	\$46,892	2009	Dr. L.D. Lynd	Dr. Carlo Marra (Co-principal Investigator)
Canadian Institute for Health Research	Mindfulness-Based Cognitive Therapy to prevent the relapse of depression in the workplace	C	\$75,000	2009	Dr. Mark Lau	Dr. L. Lynd Dr. P. McGrath Dr. Z. Segal Dr. P. Coleridge Dr. S. Ogrodniczuk
Canadian Institute for Health Research	Evaluating the association between inhaled corticosteroid and statin use on lung cancer in COPD: a BC linked health database study	C	\$125,576	2008 - 2010	Dr. L.D. Lynd	Dr. J.M. FitzGerald Dr. S. Lam Dr. C. Marra Dr. D. Sin

Canadian Institute for Health Research	Study of understanding patients' preferences on remuneration and transition towards pharmacists' provision of chronic disease management	C	\$106,861	2008 - 2010	Dr. L.D. Lynd	Dr. W. Mail Dr. C. Marra Dr. J. Taylor Dr. R. Tsuyuki
Canadian Institute for Health Research	Pharmacy-based Immunization in Rural Communities Strategy (PHICS)	C	\$150,000	2008 - 2011	Dr. Janusz Kaczorowski	Dr. P. Kendall Dr. C. Marra Dr. F. Marra Dr. R. Brunham Dr. L. Lynd
National Sanitarium Association	Respiratory Evaluation Sciences Programme	C	\$200,000 (\$1mil)	2007 - 2012	Dr. C. Marra and Dr. J.M. Fitzgerald	Dr. L. Lynd Dr. A. Anis Dr. B. Carleton
Canadian Institute for Health Research	Antidepressants and risk of suicide or self-harm in Canadian youth: A national population-based study	C	\$241,975	2008 - 2010	Dr. Yola Moride	Dr. M. Abrahamowicz Dr. R. Battista Dr. G. Galabud du Fort Dr. B. Greenfield Dr. A. Kozyrskyj Dr. J. Lelorier Dr. L. Lynd Dr. C. Metge Dr. S. Perreault
Canadian Foundation for Pharmacy	Compensation for pharmacists clinical care services – development of a sustainable, scalable and economically viable solution.	C	\$50,000 (\$100,000)	2007 - 2009	Dr. Ross Tsuyuki	Dr. L. Lynd Dr. C. Marra Dr. M. Makowsky
BC Knowledge Development Funds	Developing a Laboratory for Therapeutic Risk-Benefit Assessment	C	(\$40,000)	2006 - 2010	Dr. L.D. Lynd	
Canadian Foundation for Innovation	Developing a Laboratory for Therapeutic Risk-Benefit Assessment	C	(\$40,000)	2006 - 2010	Dr. L.D. Lynd	
MSFHR	Calculating health care costs related to asthma in British Columbia	C	\$50,000 (\$100,000)	2006 - 2008	Dr. J. Mark Fitzgerald	Dr. L. Lynd Dr. C. Marra Dr. B. Carleton
MSFHR (Team Planning Grant)	CORRECT Groups: Collaborative Resources for Research on Counseling and Therapy	C	\$25,000 (\$50,000)	2006 - 2007	Dr. John Ogrodniczuk	Dr. L. Lynd

MSFHR (Team Planning Grant)	Increasing consumer access to cognitive behaviour therapy (CBT) in British Columbia: Applying a knowledge exchange framework to CBT dissemination	C	\$25,000 (\$50,000)	2007 - 2008	Dr. Mark Lau	Dr. L. Lynd Dr. J. Ogrodniczuk Dr. Sagar Parikh Dr. Steven Hollon Dr. Dan Bilsker
MSFHR	The role of pharmacists in prescribing medications – seed funding to develop research proposal for CIHR	C	\$5000	2006	Dr. L.D. Lynd	
Pfizer Canada	Evaluating care gaps in the management of rheumatoid arthritis in British Columbia: a population based analysis	NC	\$110,219	2006	Dr. Larry Lynd Dr. Carlo Marra (Co-Principal Investigator)	Dr. D. Fielding Dr. J. Soon Dr. M. Levine
Canadian Institute for Health Research	Evaluating socioeconomic status differences in patient preferences for asthma therapy using discrete choice experimentation	C	\$292,500	2006 – 2011	Dr. L.D. Lynd	
Canadian Institute for Health Research	Population-based comparison of two regimens for emergency contraception	C	\$110,946	2005 - 2008	Dr. Marc Levine Dr. J. Soon (co-PI)	Dr. M. Ensom Dr. D. Fielding Dr. L. Lynd Dr. C. Marra
MSFHR	Establishment Grant Evaluating socioeconomic differences in patient's preferences for asthma therapy	C	\$62,500 (\$125,000)	2005 - 2007	Dr. L.D. Lynd	
Allergen	Investigating asthma among British Columbia workers: a pilot surveillance project	C	\$62,300 (\$124,600)	2005 - 2007	Dr. Mieke Kiehoorn	Dr. L. Lynd Dr. S. Kennedy Dr. J. Beach Dr. P. Demers
BC Lung Association	Antibiotic use during the first year of life and subsequent development of childhood asthma: a population-based study	C	\$30,000 (\$60,000)	2005 - 2007	Dr. F. Marra	Dr. Lynd Dr. C. Marra Dr. J.M. FitzGerald
Glaxo Smith Kline	Evaluating GINA guidelines for asthma control	NC	\$37,500 (\$75,000)	2005 - 2007	Dr. L.D. Lynd	Dr. J.M. FitzGerald
University of British Columbia	Start up Funds	NC	\$350,000	2004 – 2007	Dr. L.D. Lynd	

Vancouver Coastal Health Authority	Start up Funds	NC	\$25,000	2004 – 2007	Dr. L.D. Lynd	
BC Lung Association	Evaluating health-related quality of life and patients' preferences for treatment in asthma	C	\$45,000	2005	Dr. L.D. Lynd	Dr. C. Marra Dr. G. Currie Dr. A. Anis Dr. Tony Bai Dr. J.M. FitzGerald
Pfizer Canada Ltd.	Bayesian vs. frequent presentation of clinical trial results: impact on treatment decisions in anticoagulant therapy	C	\$25,500	2005	Dr. L.D. Lynd	
CIHR	A population-based comparison of two regimens of emergency contraception	C	\$50,000 (\$121,000)	2005	Dr. Marc Levine	Dr. C. Marra Dr. J. Soon Dr. M. Ensom Dr. D. Fielding
Cdn. Coordinating Office for Health Technology Assessment	Development of an undergraduate level course and workshop on the principles of health economics and HTA	C	\$68,165	2005	Dr. L.D. Lynd	Dr. C. Marra Dr. A. Anis Dr. D. Fielding Dr. E. Balka Mr. R. Goeree
Glaxo Smith Kline	A framework for evaluating risks and benefits of drug therapy: identification, evaluation, and development	C	\$96,000 (\$250,000)	2004	Dr. L.D. Lynd	Dr. A. Willan Dr. M. Sculphur
Providence Health Care	An evaluation of factors influencing the safety and efficacy of warfarin anticoagulation	C	\$15,000	2001	Dr. S. Shalansky Dr. Larry Lynd	
Providence Health Care	A pilot study of camouflage recruiting	C	\$6,000 (\$6,000)	2000	Dr. Aslam Anis	Dr. P. Paré Dr. L. Lynd
BC Lung Association	Socioeconomic determinants of short-acting beta- agonist use.	C	\$24,400 (\$48,800)	1998 - 2000	Dr. Aslam Anis	Dr. P. Paré Dr. T. Bai Dr. J.M. FitzGerald Dr. L. Lynd
Pharm. Manufacturers Assoc. of Canada (PMAC)	A provincial pharmacist education program on adverse drug reactions and post-marketing surveillance	NC	\$6,500 (\$6,500)	1996	Dr. L.D. Lynd	Dr. D. Daws

(c) *Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
College of Pharmacists of BC	Evaluating pharmacists working conditions in BC: replicating the Oregon experience	NC	33,550	2013	Dr. Carlo Marra Dr. Larry Lynd	
Sanofi-Aventis/ Genzyme	Evaluating treatment preferences in MS: a stated choice study	NC	\$232,470	2012	Dr. Larry Lynd	Dr. C. Marra Dr. N. Mittman Dr. C. Evans
Astra Zeneca	Evaluating pharmacist prescribing in uncontrolled asthma	NC	\$65,000	2010	Dr. Larry Lynd	
BC Pharmacy Association	Evaluation of Pharmacy Adaptation Services in British Columbia	NC	\$291,954	2009	Dr. Larry Lynd Dr. C. Marra (Co-PI)	Dr. K. Grindrod
PROOF	The potential economic impact of new strategies	NC	\$12,000	2009	Dr. Carlo Marra	Dr. L. Lynd
PROOF	Cost-effectiveness of new biomarker for rejection in heart transplant	NC	\$10,000	2009 – 2010	Dr. Carlo Marra	Dr. L. Lynd
Pharmaglyph	Randomized Controlled Trial: Pharmaglyph-Enhanced Counselling in HIV and Transplantation	NC	\$65,982	2009	Dr. Larry Lynd	Dr. C. Marra

(d) *Invited Presentations*

1. Can we move from sick-care to health-care? LSI Public Talks, Personalized Medicine: Your Life, Your Genes, Your Health and Happiness. February 4, 2015. Vancouver, BC, Canada.
2. Evaluating the implications of orphan drugs and rare diseases in Canada: A reimbursement/health care sustainability perspective. Providence Health Care Research Institute Work in Progress Seminar Series. October 22, 2014. Vancouver, BC, Canada.
3. Evaluating the implications of orphan drugs and rare diseases in Canada – a reimbursement/health care sustainability perspective. UBC Faculty of Pharmaceutical Sciences Seminar Series. October 8, 2014. Vancouver, BC, Canada.
4. Pharmacists' Working Conditions in British Columbia. College of Pharmacists of British Columbia Board Meeting. September 25, 2014. Vancouver, BC.
5. Providing professional pharmacy services in British Columbia – implementation, evaluation, and reimbursement. 15th Annual Congress of the Society Francaise de Pharmacie Clinique (SFPC). February 7, 2014. Grenoble, France.
6. Using state choice methods in health services research and evaluation. Université Joseph Fournier. February 5, 2014. Grenoble, France.
7. Decision making for pharmaceuticals – focus on orphan drug policy in Canada. Centre for Genomics and Policy, McGill University. Dec 5, 2013. Montreal, QC.
8. Reflecting on the findings of a pharmaceutical value framework workshop. Canadian Association of Population Therapeutics 2013 Annual Conference. November 17, 2013. Toronto, ON.
9. Personalized medicine, orphan disease drugs, and the future of health economics. Panelist and Speaker. The 9th World Congress on Health Economics. July 10, 2013, Sydney, Australia.
10. Where do we stand in the economics of asthma and asthma care? Asthma Symposium, in conjunction with the 9th World Congress on Health Economics. July 6, 2013, Sydney, Australia.

11. Evaluation of outcomes associated with a continuing professional development program in maternal and child health in Rwanda. Inter-professional collaborative teamwork and clinical teaching workshop on Maternal, Newborn and Child Health. October 16-17, 2012. Kigali, Rwanda.
12. Positive patient outcomes through partnerships and collaborations – government, industry, and academia. Social and Administrative Pharmacy Educators of Canada Annual Meeting. October 9-10, 2012, Montreal QC.
13. Developing a Canadian Framework for Evaluation and Decision-Making for Expensive Drugs for Rare Diseases Through Innovation, Value, and Priority Setting. 2012 Rare Disease Day Conference February 20 – March 1, 2012. Ottawa, ON, Canada.
14. The economics of asthma: it's about more than the dollars (Keynote). 1st International Symposium on the Economics of Asthma and Asthma Care, in conjunction with the 8th World Congress on Health Economics. July 9, 2011. Toronto, ON, Canada
15. Evaluating patients' preference for pharmacist provision of chronic disease management using a discrete choice experiment. Canadian Pharmacists Association National Conference May 28-31, 2011, Montreal, Quebec.
16. Integrating benefit and risk data into decision-making. 32nd Annual Society of Clinical Trials Meeting. May 16, 2011. Vancouver, BC.
17. Exploring the international landscape of new methods for benefit-risk assessment. Canadian Association of Population Therapeutics Annual Conference. April 19, 2011. Ottawa, ON.
18. Economic evaluation and cost effectiveness analysis – the 4th hurdle in drug development. Centre for Drug Research and Development Seminar. Vancouver, BC. March 21, 2011.
19. Risk benefit analysis: combination LABA+ICS vs ICS alone for the treatment of asthma. 3rd Annual UBC Centre for Lung Health Research and Policy Day. March 26, 2010. Vancouver, BC.
20. Platform for Outcomes Research and Translation in Asthma and Allergy. Allergen Network Wide Research Workshop. Toronto, ON. Dec 18, 2009.
21. Incremental net benefit case studies. US FDA/DIA: Assessing benefits and risks of medicinal products in regulatory decisions. Bethesda, MD. Nov. 4, 2009
22. Incremental net benefit for quantifying benefit-risk tradeoffs. US FDA/DIA: Assessing benefits and risks of medicinal products in regulatory decisions. Bethesda, MD. Nov. 3, 2009.
23. Applications of incremental net benefit to quantitative risk benefit analysis. The future of drug safety research: an interdisciplinary environment. Erasmus University. Erasmus Expo and Congress Centre. October 31, 2008.
24. Applications of pharmacoeconomics to re-imburement of expensive drugs for rare diseases. BC Ministry of Health Expensive Drugs for Rare Disease Advisory Committee. Vancouver, BC. October 7, 2008.
25. The economics of drug coverage in Canada. UBC Dept. of Medicine Internal Medicine Residents Whistler Conference. Advocacy in Action. March 6, 2008.
26. Case studies using incremental net benefit for risk-benefit analysis. At: Joint FDA, PhRMA, BIO working conference: Assessing drug benefits and risks in regulatory decisions: framed the need, evaluating the tools, and deciding next steps. Washington, DC. November 7 & 8, 2007.
27. Using incremental net benefit for quantitative benefit-risk analysis – case studies of Vioxx® and Lotronex®. At: Office of Health Economics/ European Medicines Evaluation Agency Workshop: "How can regulatory agencies improve the risk-benefit assessment of pharmaceuticals? Does an economic perspective help? London, England. October 24, 2007.
28. An introduction to pharmacoepidemiology: an overview and examples. Pfizer Canada, Inc. Vancouver, BC. July 11, 2007.
29. Using incremental net-benefit for quantitative risk-benefit analysis. Presented at: Drug Information Association 43rd Annual Meeting, June 18, 2007. Atlanta, GA.
30. Pharmaceutical reimbursement policies for drug therapy for children with asthma in British Columbia, in: Public Health, Policy and Society Workshop on Improving Drug Benefits for Children with Asthma: Building a Research Agenda. March 27 – 28, 2007. Toronto. ON. (Presenter and Panelist).
31. Quantitative methods for therapeutic benefit risk assessment. FDA/Regenstrief Institute joint meeting on Benefits and Risks of Pharmaceuticals: Frameworks, Methods and Policies. March 15-15, 2007, Washington, DC. (Presenter and Panelist)
32. Methods in quantitative risk benefit analysis. In: Advance Topics in Pharmacoepidemiology. 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment. August 24, 2006. Lisbon, Portugal.

33. Quantitative methods for therapeutic risk-benefit analysis. International Society of Pharmacoeconomics and Outcomes Research Annual meeting. May 22, 2006. Philadelphia, PA. (Presenter and Panelist)
34. Methodologic approaches to risk-benefit analysis. 3rd Canadian Therapeutic Congress. Hilton Toronto. Toronto, ON. May 10, 2006.
35. FDA round-table discussion on benefit-risk assessment of pharmaceuticals. PhRMA/FDA joint meeting. May 2, 2006. Washington, DC. (Presenter and Panelist)
36. Metrics for benefit-risk assessment. International Society for Pharmacoepidemiology 2006 Midyear Meeting. Washington, DC. April 24, 2006.
37. A systematic review and evaluation of methods for risk-benefit analysis; the results of Phase I. GlaxoSmithKline Global Health Outcomes Annual Meeting. Fiuggi, Italy. April 20, 2005.
38. Quantitative methods for risk benefit analysis. GlaxoSmithKline Global Clinical Scientific and Pharmacovigilance Group. Philadelphia, PA. March 24, 2004.
39. Risk-benefit analysis: the past, the present, and paving the way of the future. Grand rounds. Dept. of Health Care and Epidemiology, Faculty of Medicine, University of British Columbia. Vancouver, BC. January 21, 2004.
40. Taking calculated risks: an innovative approach to risk assessment. Plenary speaker. Canadian College of Clinical Pharmacy Annual Meeting. Winnipeg, MB. June 3, 2004.
41. Asthma control in British Columbia: is it a problem, and what is causing the problem. University of British Columbia Faculty of Pharmaceutical Sciences Research Seminar. Vancouver, BC. February 26, 2002.
42. Tackling the difficult patient – case challenges in asthma. Clearing the Air on Asthma conference. Burnaby, BC. November 4, 2001.
43. Using the Pharmacare database to assess the appropriateness of asthma medication use. University of British Columbia Respiratory Division Research Seminar Series, 2000-2001. St. Paul's Hospital, Vancouver, BC. October 24, 2001.
44. Setting the stage: asthma management in British Columbia. BC Asthma Educators 4th Annual Retreat. Vancouver, BC, Canada. Oct 12-13, 2001.
45. Exploring the relationship between socioeconomic status and short-acting beta-agonist use in British Columbian asthmatics. Research In Progress rounds. St. Paul's Hospital, Vancouver, BC. Sept 24, 2001.
46. Double trouble: inappropriate asthma medication use linked to increased use of health care resources. Vancouver and area Respirologists Quarterly Journal Club. Vancouver, BC. August 8, 2001.
47. Beta-agonist utilization patterns in British Columbia: analysis of BC Pharmacare data. Glaxo-Wellcome expert advisory committee meeting. Vancouver, BC. October 8, 2000.
48. Confounding in clinical research. Doctor of Pharmacy Seminar. Faculty of Pharmaceutical Sciences, University of British Columbia. March, 2000.
49. A longitudinal analysis of β -agonist use in British Columbia. Research in Progress rounds. St. Paul's Hospital, Vancouver, BC. March 2000.
50. Bias in clinical research. Doctor of Pharmacy Seminar. Faculty of Pharmaceutical Sciences, University of British Columbia. February, 2000.
51. The "How To" of detecting bias and confounding in clinical trials. BC Drug and Poison Information Centre drug information rounds. St. Paul's Hospital. Vancouver, BC. October 17, 1999.
52. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. Kelowna, BC. May 1997.
53. Adverse drug reactions – the role of the physician in post-marketing surveillance. Medical Grand Rounds. Kelowna General Hospital, Kelowna, BC. May, 1997.
54. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. Terrace, BC. May 1997.
55. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. Trail, BC. March, 1997.
56. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. Penticton, BC. March, 1997.
57. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. Abbotsford, BC. February, 1997.
58. Adverse drug reactions and post-marketing surveillance - how pharmacists can contribute to drug safety. Canadian Society of Hospital Pharmacists – BC Branch February Program. Vancouver, Feb 26, 1997.

59. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. Sechelt, BC. January, 1997.
60. Adverse drug reaction reporting and post-marketing surveillance - how health care professionals can contribute to drug safety. BC Provincial Continuing Pharmacy Education Series. Salmon Arm, BC. December, 1996.
61. Adverse drug reactions in the long term care population. New Ideas for Old Friends - BC's Long Term Care Pharmacy Conference. Vancouver, May 1996.
62. Adverse drug reactions and interactions - a focus on ACE Inhibitors and herbal drugs. Pharmacy Evening Continuing Education Lecture Series, Victoria, BC. November, 1996
63. Adverse drug reactions and interactions - identification and management. A focus on calcium channel blockers. Pharmacy Evening Continuing Education Lecture Series, Victoria, BC. March, 1996

(e) *Other Presentations*

Panel Participant/Presentations

1. Lau M, Williams C, Hollon S, Lynd LD. Transporting CBT from the research clinics to the providers and consumers who want and need them: what we have done, and what we still need to do. 45th Annual Convention of the Association of Behavioural Cognitive Therapists. Nov. 10, 2011. Toronto, ON (peer reviewed)
2. Van Staa, TP, Lynd LD, Leufkens HGM, Raine J, Petri, H. Benefit-harm modeling: What is this and what can it contribute to pharmacovigilance? 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Copenhagen, Denmark, August 17 – 20, 2008. (peer reviewed)
3. Invited participant. Next-steps working group on FDA benefit-risk assessment. Washington, DC. March 14, 2008.
4. Ogrodniczuk JS, Lynd LD, Richardson K. Day treatment for personality disorder: Predicting premature termination. Panel Presentation. Society for Psychotherapy Research. Thirty-seventh Annual Meeting, Edinburgh, Scotland, June 24, 2006. (Peer reviewed)
5. Health outcomes approaches to risk-benefit analysis: How ready are they. Issues Panel. International Society for Pharmacoeconomics and Outcomes Research, 11th Annual International Meeting. Philadelphia, PA. May 23, 2006. (Peer reviewed)
6. Stakeholder roundtable: optimizing benefit risk assessment. Invited participant. Scientific and Regulatory Executive Committee of the Pharmaceutical Research Manufacturers of America (PhRMA) and US Food and Drug Administration. Washington, DC. May 2, 2006. (Invited)

(f) *Other*

Workshops Presented

1. Outcomes evaluation of the UWO/KHI/NUR/MOH Continuing Medical Education program in Maternal, Newborn, and Child Health in the Eastern District of Rwanda. October 16-17, 2012. Kigali, Rwanda.
2. Vancouver short course on health economics and health care coverage decision-making. Vancouver, BC, November 24-25, 2011.
3. Health Economic Evaluation and Coverage Decision Making. November 24 – 25, 2010. Vancouver, BC.
4. Applications of quantitative risk benefit analysis to regulatory decision making. October 30, 2008. Erasmus University, Rotterdam, Netherlands.
5. Collaboration for Outcomes Research and Evaluation Inter-professional Health Economics Workshop. October 2 – 3, 2008. Vancouver, BC, Canada.
6. Introduction to economic evaluations in health. Half-day workshop. Vancouver Coastal Health Research Institute. Vancouver General Hospital, May 2007.
7. Pharmacoeconomics and drug policy decision-making: a primer for pharmacists. Sheraton Wall Centre, February 3, 2007. Vancouver, BC.
8. Quantitative methods for therapeutic risk-benefit analysis – focus on rofecoxib. For: Merck Frosst, Inc. November 17, 2006. Philadelphia, PA.
9. Facilitator: Advanced modeling methods for health economic evaluation. Toronto Renaissance Skydome. Toronto, ON. June 21-23, 2006

10. Drugs, devices and procedures: Getting what you need – the assessment of technology in health. Regina Qu'Appelle Regional Health District. Regina, SK. June 8, 2006.
11. Introduction to economic evaluation for clinicians. For: Vancouver Coastal Health and Vancouver General Hospital. April 11, 2006.
12. Evidence-based medicine workshop: avoiding harm, explaining harm. Canadian College of Clinical Pharmacy Annual Meeting. Winnipeg, MB. June 3, 2004.
13. Workshop Coordinator. Using administrative databases for health outcomes research. Centre for Health Evaluation and Outcome Sciences Workshop. St. Paul's Hospital. Vancouver, BC, Canada. June 21, 1999.

Continuing Education Events Developed and Presented

1. Lynd LD, FitzGerald JM. Patients' preferences for the effective control of asthma. October 10, 2006, Vancouver, BC. 1.5 CEUs. (14 attendees)
2. Lynd LD, FitzGerald JM. Patients' preferences for the effective control of asthma. October 23, 2006, Kamloops, BC. 1.5 CEUs. (13 attendees)
3. Lynd LD, FitzGerald JM. Patients' preferences for the effective control of asthma. October 24, 2006, Kelowna, BC. 1.5 CEUs. (18 attendees)

(g) *Conference Participation (Organizer, Keynote Speaker, etc.)*

Member, Organizing Committee, Asthma Symposium 2011, 1st International AllerGen Symposium on Asthma and Economics, iHEA Congress, Toronto, Canada.

Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2004-2005, 2009-2010.

Member, Scientific Program Committee, Canadian Association of Population Therapeutics, 2004-2005.

Member, Annual Conference Scientific Program Committee, Canadian Association of Population Therapeutics, 2003-2004.

Co-Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2003-2004.

10. SERVICE TO THE UNIVERSITY

(a) *Memberships on committees, including offices held and dates*

Committee	Faculty/Dept	Dates
Member – Selection Committee – FoPS-NH Partner position with Northern Health – Research & Development Pharmacists, Primary Care	UBC, Faculty of Pharmaceutical Sciences	2014
Member – Search Committee – Nutritional Epidemiologist	UBC, Faculty of Land and Food Systems	2013-14
Chair – Search Committee – Professorship in Health Care Sustainability	UBC, Faculty of Pharmaceutical Sciences	2012- 2013
Member – Pharmacist Clinic RFP Evaluation Committee	UBC, Faculty of Pharmaceutical Sciences	2012
Member – Professionalism Committee	UBC, Faculty of Pharmaceutical Sciences	2012 - ongoing
Member – Early Career Scholar Adjudication Committee	UBC, Peter Wall Institute for Advanced Studies	2012
Member – CRC Search Committee	UBC, Faculty of Pharmaceutical Sciences	2011-12

Member – Faculty Executive Committee	UBC, Faculty of Pharmaceutical Sciences	2010 - ongoing
Member, Graduate Scholarship Selection Committee	UBC, Faculty of Pharmaceutical Sciences	2009 - ongoing
Member - Merit Committee	UBC, Faculty of Pharmaceutical Sciences	2009 - ongoing
Member, Research Committee	UBC, Faculty of Pharmaceutical Sciences	2005 - ongoing
Chair (2009-2011), Bernie Riedel Golf Tournament Committee	UBC, Faculty of Pharmaceutical Sciences	2006- ongoing
Member, New Building Committee	UBC, Faculty of Pharmaceutical Sciences	2007 - 2010
Interviewer – Undergraduate Student Entrance Interviews	UBC, Faculty of Pharmaceutical Sciences	2006 – 2010

(b) *Other service, including dates*

1. Network Investigator, Allergen NCE (National Centre of Excellence), 2008 - ongoing
2. Affiliate, Centre for Health Care Management (UBC), 2007 - ongoing
3. Research Scientist, Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, 2007 - ongoing
4. Associate Professor, Faculty of Medicine, School of Population and Public Health(UBC), 2005 - ongoing
5. Research Scientist, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 2004 - ongoing
6. MSc/PhD Student-Faculty Representative (appointed), Dept. of Health Care and Epidemiology, UBC 1998 - 2000
7. Graduate Education Committee Student Representative (appointed) Faculty of Medicine, UBC 1998 - 2002

11. **SERVICE TO THE COMMUNITY**

(a) *Memberships on scholarly societies, including offices held and dates*

Member of the Board (elected), Canadian Association of Population Therapeutics, 2002 - 2007
Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2004 - 2005, 2009 - 2010
Member, Scientific Program Committee, Canadian Association of Population Therapeutics, 2004 - 2005
Member, Annual Conference Scientific Program Committee, Canadian Association of Population Therapeutics, 2003 - 2004
Co-Chair, Scientific Evaluation Committee, Canadian Association of Population Therapeutics, 2003 - 2004
Member, American Thoracic Society
Member, Society for Medical Decision-making
Member, International Society for Outcomes Research
Member, International Society for Pharmacoepidemiology
Member, Canadian Pharmacists' Association

(b) *Memberships on other societies, including offices held and dates*

(c) *Memberships on scholarly committees, including offices held and dates*

Member, Pharmacy Examining Board of Canada Panel of Examiners, 2009 - ongoing (appointed)
Reviewer, Allied Health Researcher Fellowship Review Committee, Canadian Institutes for Health Research, 2006 - ongoing

Member, MSFHR Population Health Research Fellowship Review Committee, Michael Smith Foundation for Health Research, 2006 - ongoing

Member, Strategic Planning Committee, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, 2004 - 2007

(d) *Memberships on other committees, including offices held and dates*

Provincial

Member, BC Health Authorities Provincial Pharmacy & Therapeutics Appeals Committee, 2011 - ongoing

Member, BC Health Authorities Provincial Pharmacy & Therapeutics Committee, 2009 - 2011

Member, BC Ministry of Health Expensive Drugs for Rare Diseases Committee (appointment); 2008 - ongoing

Member, Member BC College of Pharmacists PharmaNet Data Access Committee (appointment), 2007- 2012

National

Member, Expert Advisory Committee on the Vigilance of Health Products, Health Products and Food Branch, Health Canada, 2012 - ongoing (appointed)

Chair, Health Canada Scientific Advisory Committee on Nonprescription Drugs (SAC-NPD), 2011 - ongoing

Member, Expert Advisory Committee to Health Canada – Respiratory and Allergy Medicines, 2006 - ongoing

Member, National Drug Scheduling Advisory Committee member (appointment), National Association of Pharmacy Regulatory Authorities, 2001 - 2009

International

Next Steps working group on FDA benefit-risk assessment (Invited), 2007 - ongoing

Member, Executive Council, the Friends of Rwanda Forum, March 2013 - ongoing

(e) *Editorships (list journal and dates)*

(f) *Reviewer (journal, agency, etc. including dates)*

Medical Decision Making, 2005 - ongoing

Pharmacoepidemiology and Drug Safety, 2004 - ongoing

Canadian Journal of Hospital Pharmacy, 2000 - ongoing

Health Policy, 2010

The Canadian Medical Association Journal, 2006 - 2010

The Annals of Pharmacotherapy, 2005- ongoing

The Canadian Journal of Public Health, 2008

Canadian Medical Association Journal, 2009 - 2011

Canadian Journal of Emergency Medicine, 2009

Value in Health, 2006 – ongoing

(g) *External examiner (indicate universities and dates)*

Student Name	Program Type	Date	University/Role
Meghan Gregg	M.Sc.	2012	McMaster/External Examiner
Gillian Hanley	Ph.D.	2011	UBC/ University External examiner
Marion Pearson	M.Sc.	2008	UBC/ University External examiner
Samantha Bowker	Ph.D. (UofA)	11/07	U of A/ External examiner – comprehensive exam
Jennifer Rose St. Onge	Ph.D.	12/2011	Thesis Committee chair, Oral Exam chair

(h) *Consultant (indicate organization and dates)*

1. Consultant, Sanofi-Aventis Canada, 2011 – ongoing
2. Consultant, BC Pharmacy Association (re: pharmacists' remuneration strategies), 2009–2011
3. Consultant, Pfizer Canada, Inc., 2009 – ongoing
4. Consultant, BC Provincial Health Services Authority (re: cost benefit analysis of providing cognitive behavior therapy), 2008 - 2011
5. Consultant, Therapeutics Products Directorate, Health Canada, 2005-2006
6. Consultant Glaxo Smith Kline, Novartis, 2004-2005, 2009-2010
7. Consultant, Office of Drug Safety, US Food and Drugs Administration, 2005 - ongoing
8. Consultant, Advertising Standards Canada, 2004 - ongoing
9. Consultant, Effectiveness/Cost effectiveness of anti-rejection drug therapy, BC Transplant Society, 2001-2002
10. Consultant/ Expert Witness British Columbia Coroner's Office, 1994- 001

(i) *Other service to the community*

Tenure and Promotion Review – Dr. Daria O'Reilly, McMaster University, July 2012.

12. AWARDS AND DISTINCTIONS

(a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

Teaching Scholarship, Faculty Certificate Program in Advanced and Higher Education, UBC, 2005
Program Instructor Award, Faculty of Pharmaceutical Sciences Doctor of Pharmacy (PharmD), UBC, 2013

(b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

Name of Award	Organization	Date
PharmD Teaching Award	Faculty of Pharmaceutical Sciences	2013
Publication Award – Research Article	Canadian Society of Hospital Pharmacists – BC Branch	2012
Early Career Scholar	Peter Wall Institute for Advanced Studies	2011
Specialties in Pharmacy Practice Award	Canadian Society of Hospital Pharmacists	2008
New Investigator Award	Canadian Institutes of Health Research	2006
Career Scholar Award (\$80,000/yr x 5 years)	Michael Smith Foundation for Health Research	2005
Post-Doctoral Fellowship (\$47,500/yr salary support, \$3,500/yr research allowance – 2 years. (Ranked No.1)	Canadian Institutes for Health Research (Peer Reviewed)	2003
Doctoral Trainee Award (\$16,000 / year – 1 year)	Michael Smith Foundation for Health Research (Peer Reviewed)	2002
Doctoral Fellowship Award (\$45,000/year salary support, \$3,500/year research allowance – 2 years)	Canadian Institutes for Health Research (Peer Reviewed)	2000
George R.F Elliot Fellowship in Community Health - \$7,500.	Dept. of Health Care and Epidemiology. University of British Columbia/ BC Medical Service	1999

	Foundation (Peer-reviewed)	
Health Care and Epidemiology Alumni Association Scholarship - \$850. (<i>Scholarship for PhD students with First Class Standing in first 2 years of course work</i>)	Dept. of Health Care and Epidemiology Alumni Association	1999
John Snow Prize \$100 (<i>Highest standing in Epidemiology course HCEP 502</i>)	Dept. of Health Care and Epidemiology, University of British Columbia	1998
University Graduate Fellowship (<i>Awarded to top 10% of students in Graduate studies applying – \$16,000/yr x 2yrs.</i>)	University of British Columbia (peer reviewed)	1998 (Declined)
Medical Research Council of Canada/Canadian Drug Manufacturers Association Studentship (\$16,500/yr - 4 years.)	Medical Research Council of Canada/ Canadian Drug Manufacturers Association (peer-reviewed)	1997
Canadian Foundation for Pharmacy Past President's Award - \$750 (<i>Awarded to student in Pharmacy at a Canadian University selected for outstanding academic achievement and deemed most likely to succeed and contribute to the profession of pharmacy over their career</i>)	Canadian Foundation for Pharmacy	1986

(c) Awards for Service (*indicate name of award, awarding organizations, date*)

(d) Other Awards

Best Paper Award, Canadian Pharmacists Journal, 2012

Centennial Alumni of Influence Award, University of Saskatchewan College of Pharmacy and Nutrition, 2014

13. OTHER RELEVANT INFORMATION (Maximum One Page)

THE UNIVERSITY OF BRITISH COLUMBIA
Publications Record

SURNAME: Lynd

FIRST NAME: Larry
MIDDLE NAME(S): DavidInitials: LDL
Date: January 2015**1. REFEREED PUBLICATIONS**

Underlined designates student or trainee: Students and trainees are have been underlined in the following list of publications. In order to facilitate their career development, it has always been my philosophy to support and assist students in the development of their publication record. In this regard, where ever possible, I allow my students and trainees to be first authors on any publications where they participated significantly in the conceptualization, design, and manuscript preparation. In each instance, I have assumed either the second or anchor author position and am the senior and corresponding author.

Journal	Thompson-Reuters SciCitInx Impact Factor
Annals of Pharmacotherapy	2.45
Arthritis Care and Research	4.851
BioMedCentral Health Services Research	1.66
BioMedCentral Pulmonary Medicine	2.04
Canadian Journal of Psychiatry	2.5
Canadian Medical Association Journal	7.27
Canadian Respiratory Journal	1.556
Chest	5.25
Clinical and Applied Thrombosis/Hemostasis	1.332
Diabetes Technology and Therapeutics	1.931
Drug Development and Industrial Pharmacy	1.494
European Journal of Epidemiology	4.713
Genetic Medicine	4.762
Health Economics	2.123
Heart Rhythm	4.045
International Journal of Technology Assessment in Health Care	1.79
J Arthroplasty	2.11
J Asthma Allergy and Clinical Immunology	12.05
Journal of Asthma	1.37
Journal of Cardiovascular Electrophysiology	3.064
Journal of Clinical Epidemiology	4.271
Journal of Rheumatology	3.695
Patient Preference and Adherence	1.143
Pediatrics	5.437
Pharmacoeconomics	2.663
Pharmacoepidemiology and Drug Safety	2.528
Pharmacotherapy	2.631
PLOS One	4.411
Psychotherapy and Psychosomatics	5.37
Quality of Life Research	2.3
Respiratory Research	3.36
Rheumatology	4.058
Value in Health	2.191

(a) *Journals*

1. Dionne F, Mitton C, Dempster B, **Lynd L**. Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward. *J Pop Ther Clin Pharmacol*. January 2015. In press.
2. Douglas CMW, Wilcox E, Burgess M, **Lynd LD**. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. *Health Policy*. January 2015, in press. <http://dx.doi.org/10.1016/j.healthpol.2015.01.009>
3. Dragojlovic N, Rizzardo S, Bansback N, Mitton C, Marra CA, **Lynd LD**. Challenges in measuring the societal value of orphan drugs: insights from a Canadian stated preference survey. *Patient*. 2015 Jan 14. [Epub ahead of print] PMID: 25586645
4. Sadatsafavi M, **Lynd LD**, De Vera MA, Zafari Z, FitzGerald JM. One-year outcomes of inhaled controller therapies added to systemic corticosteroids after asthma-related hospital discharge. *Respir Med*. 2015 Jan 7. pii: S0954-6111(14)00452-1. doi: 10.1016/j.rmed.2014.12.014. [Epub ahead of print] PMID: 25596136
5. De Vera MA, Sadatsafavi M, Tsao NW, **Lynd LD**, Lester R, Gastonguay L, Galo J, FitzGerald JM, Brasher P, Marra CA. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial. *Trials*. 2014 Dec 13;15:488. doi: 10.1186/1745-6215-15-488. PMID: 25494702
6. Whitfield KC, Karakochuk CD, Liu Y, McCann A, Talukder A, Kroeun H, Ward M, McNulty H, **Lynd LD**, Kitts DD, Li-Chan ECY, McLean J, Green TJ. Poor thiamin and riboflavin status is common among women of childbearing age in rural and urban Cambodia. *Journal of Nutrition*. 2015 Jan 7. doi: 10.3945/jn.114.203604. [Epub ahead of print]
7. Brown KM, Fenton NE, **Lynd LD**, Marra CA, FitzGerald MJ, Harvard SS, Rosenthal M, Chow BYL, Clarke AE, Elliott SJ. Canadian policy on food allergen labelling: Consumers' perspectives regarding unmet needs. *Universal Journal of Public Health*. December 2014, accepted.
8. Trenaman L, Sadatsafavi M, Almeida F, Ayas N, **Lynd L**, Marra C, Stacey D, Bansback N. Exploring the potential cost-effectiveness of patient decision aids for use in adults with obstructive sleep apnea: A case study. *Med Decis Making*. 2014 Oct 24. pii:0272989x14556676. [Epub ahead of print] PMID: 25344130.
9. Dragoljovic N, **Lynd LD**. Crowdfunding drug development: the state of play in oncology and rare diseases. *Drug Discov Today*. 2014 Nov;19(11):1775-1780. doi: 10.1016/j.drudis.2014.06.019. PMID: 24973645
10. Bansback N, Li LC, **Lynd L**, Bryan S. Development and preliminary user testing of the DCIDA (Dynamic computer interactive decision application) for 'nudging' patients towards high quality decisions. *BMC Med Inform Decis Mak*. 2014 Aug 1:14:62. PMID: 25084808
11. McDonald CM, McLean J, Kroeun H, Talukder A, **Lynd LD**, Green TJ. Household food insecurity and dietary diversity as correlates of maternal and child undernutrition in rural Cambodia. *European J of Clin Nutrition*. 2014 August 13. doi: 10.1038/ejcn.2014.161 PMID: 25117993
12. Tsao NW, Marra CA, **Lynd LD**, Thomas JM, Ferreira E. Community pharmacist surveillance of hypertension in pregnancy. Are we ready for prime time? *Canadian Pharmacists Journal*. 2014 Sep;147(5):307-15. doi: 10.1177/1715163514543898 PMID: 25364340
13. Zafari Z, **Lynd LD**, FitzGerald JM, Sadatsafavi M. Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma. A simulation study. *J Allergy Clin Immunol*. 2014 Oct;134(4):908-915. PMID: 24875619.

14. Bansback N, Li L, **Lynd LD**, Bryan S. Exploiting order effects to improve the quality of decisions. *Patient Educ Couns*. 2014 Aug;96(2):197-203. doi: 10.1016/j.pec.2014.05.021 PMID: 24961445
15. Ungar WJ, Hadioonazadeh A, Najafzadeh M, Tsao NW, Dell S, **Lynd LD**. Quantifying preferences for asthma control in parents and adolescents using best-worst scaling. *Respiratory Medicine*. 2014 Jun;108(6):842-51. doi.org/10.1016/j.rmed.2014.03.014. PMID: 24780719
16. Henrich N, Marra CA, Gastonguay L, Mabbott D, Malkin D, Fryer C, Bouffet E, Taylor M, Hukin J, Scantlebury N, **Lynd L**. De-escalation of therapy for pediatric medulloblastoma: trade-offs between quality of life and survival. *Pediatr Blood Cancer*. 2014 Jul;61(7):1300-4. doi: 10.1002/pbc.24990. PMID: 24616367
17. Marra F, Kaczorowski J, Gastonguay L, Marra CA, **Lynd LD**, Kendall P. Pharmacy-based immunization in rural communities strategy (PhICS): a community cluster randomized trial. *Can Pharm J*. 2014;147(1):33-44 PMID: 24494014
18. Sadatsafavi M, Rousseau R, Chen W, Zhang W, **Lynd L**, FitzGerald JM. Economic Burden of Asthma (EBA) study team. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. *Chest*. 2014; 145(4): 787–93. PMID: 24337140
19. Sadatsafavi M, **Lynd LD**, FitzGerald JM. Post-hospital syndrome in adults with asthma: a case-crossover study. *Allergy Asthma Clin Immunol*. 2013 Dec 23;9(1):49. doi: 10.1186/1710-1492-9-49. PMID: 24364886
20. Najafzadeh M, Johnston MK, Peakcock JS, Connors MJ, Marra MA, **Lynd LD**, Marra CA. Genomic testing to determine drug response: measuring preferences of the public and patients using a discrete choice experiment. *BMC Health Serv Res*. 2013 Oct 31;13(1):454. PMID: 24176050.
21. Davis EM, **Lynd LD**, Grubisic M, Kopec JA, Sayre EC, Cibere J, Esdaile J, Marra CA. Responsiveness of health state utility values in knee osteoarthritis. *J Rheumatol*. 2013; 40 (12):2075-82. PMID: 24187098.
22. Bashir J, Cowan S, Raymakers A, Yamashita M, Danter M, Krahn A, **Lynd LD**. A cost-effectiveness analysis of a proactive management strategy for the Sprint Fidelis recall: a probabilistic decision analysis model. *Heart Rhythm*, 2013 Dec;10(12):1761-7. PMID: 24076445.
23. Sweeney K, Grubisic M, Marra CA, Kendall R, Li L, **Lynd LD**. Comparison of HRQL Between Unicompartmental Knee Arthroplasty and Total Knee Arthroplasty for the Treatment of Osteoarthritis. *J Arthroplasty*. 2013 Oct;28(9 Suppl):187-190. PMID: 23850408
24. Sadatsafavi M, **Lynd LD**, Marra CA, FitzGerald JM. Dispensation of long-acting beta agonists with or without inhaled corticosteroids and risk of asthma-related hospitalisation: a population-based study. *Thorax*. 2014 Apr;69(4):328–34. doi:10.1136/thoraxjnl-2013-203998. PMID: 24281327.
25. Chen W, FitzGerald JM, Rousseau R, **Lynd LD**, Tan WC, Sadatsafavi M. Complementary and alternative asthma treatments and their association with asthma control: a population-based study. *BMJ Open*. 2013 Sep 4;3(9):e003360. doi :10.1136/bmjopen-2013-003360. PMID: 24005131.
26. Najafzadeh M, Marra CA, **Lynd L**, Wiseman S. Authors' response to "comparative effectiveness and personalized medicine" by Dr. J.D. Hornberger. *Value Health*. 2013 Jun;16(4):697. doi:10.1016/j.jval.2013.02.005. PMID: 23796305.

27. Cloutier A-M, Greenfield B, Lavoie A, **Lynd LD**, Tournier M, Brabant M-J, Moride Y. Effectiveness of risk communication interventions on the medical follow-up of youth treated with antidepressants. *Psychiatry Research*. 2013 Oct 30;209(3):471-8. doi:10.1016/j.psychres.2012.12.029. PMID: 23664663.
28. Sadatsafavi M, **Lynd LD**, Marra CA, Bedouch P, FitzGerald M. Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthma: a population-based study. *J Allerg Asthma Clin Immunol*. 2013 Jul;132(1): 63-9. doi:10.1016/j.jaci.2013.02.007. PMID: 23545275.
29. Sadatsafavi M, FitzGerald JM, Marra CA, **Lynd LD**. Costs and health outcomes associated with primary versus secondary care after an asthma-related hospitalization, a population-based study. *Chest*. 2013 Aug;144(2):428-35. doi:10.1378/chest.12-2773. PMID: 23519289.
30. Koehoorn M, Tamburic L, McLeod CB, Demers PA, **Lynd L**, Kennedy SM. Population-based surveillance of asthma among workers in British Columbia, Canada. *Chronic Dis Inj Can*. 2013 Mar;33(2):88-94. PMID: 23470174.
31. Bedouch P, Marra CA, FitzGerald JM, Sadatsafavi M, **Lynd LD**. Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study. *PLoS ONE*. 2012;7(12):e50949. doi:10.1371/journal.pone.0050949. PMID: 23227222.
32. Najafzadeh M, Marra CA, **Lynd LD**, Wiseman SM. Cost-effectiveness of using a molecular diagnostic test to improve pre-operative diagnosis of thyroid cancer. *Value Health*. 2012 Dec;15(8):1005-13. doi:10.1016/j.jval.2012.06.017. PMID: 23244801.
33. Sadatsafavi M, Marra CA, Marra F, Moran O, FitzGerald JM, **Lynd LD**. A quantitative benefit risk analysis if isoniazid (INH) for treatment of latent tuberculosis infection (LTBI) using incremental net-benefit framework. *Value in Health*. 2013 Jan-Feb;16(1):66-75. PMID: 23337217.
34. Najafzadeh M, Marra CA, **Lynd LD**, Sadatsafavi M, FitzGerald JM, McManus B, Sin D. Future impact of Various Interventions on the burden of COPD in Canada: A dynamic population model. *PlosOne*. 2012;7(10): e46746. doi:10.1371/journal.pone.0046746. PMID: 23071626.
35. Almeida FR, Henrich N, Marra C, **Lynd LD**, Lowe AA, Tsuda H, Fleetham JA, Pliska B, Ayas N. Patient preferences and experiences of CPAP and oral appliances for the treatment of obstructive sleep apnea: a qualitative analysis. *Sleep Breath*. 2013 May;17(2):659-66. doi:10.1007/s11325-012-0739-6. PMID: 22833346.
36. Lau M, Colley L, Willett B, **Lynd LD**. Employee's preferences for access to Mindfulness-based Cognitive Therapy to reduce the risk of depressive relapse - a discrete choice experiment. *Mindfulness*. 2012;3(4): 318-26.
37. Marra CA, **Lynd LD**, Colley L, Harvard SS, Lacaille D, Schwenger E, Anis AH, Esdaile JM. Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. *J Rheumatol*. 2012 May;39(5):910-5. doi:10.3899/jrheum.110604. PMID: 22422500.
38. Marra CA, **Lynd LD**, Grindrod KA, Joshi P, Isakovic A. Evaluating the labour costs associated with pharmacy adaptation services in British Columbia. *Can Pharm J (Ott)*. 2012 Mar;145(2):78-82.
39. Najafzadeh M, **Lynd LD**, Davis JC, Bryan S, Anis A, Marra M, Marra CA. Barriers to integrating personalized medicine into clinical practice: a best-worst scaling choice experiment. *Genet Med*. 2012 May;14(5):520-6. doi:10.1038/gim.2011.26. PMID: 22241089.
40. Wilby K, Marra CA, da Silva JH, Grubisic M, Harvard S, **Lynd LD**. Randomized Controlled Trial Evaluating Pictogram Augmentation of HIV Medication Information. *Ann Pharmacother*. 2011 Nov;45(11):1378-83. doi:10.1345/aph.1Q091. PMID: 22028420.
41. Marra F, Marra CA, Richardson KJ, **Lynd LD**, Fitzgerald JM. Antibiotic Consumption in Children Prior to Diagnosis of Asthma. *BMC Pulmonary Medicine*. 2011 May 31;11:32. doi:10.1186/1471-2466-11-32.

PMID: 21627795.

42. Marra CA, **Lynd L**, Harvard S., Grubisic M. Agreement between aggregate and individual-level measures of income and education: a comparison across three patient groups. *BMC Health Services Research*. 2011 Mar 31;11:69. doi:10.1186/1472-6963-11-69. PMID: 21453534.
43. Ogrodniczuk JS, **Lynd LD**, Joyce AS, Grubisic M, Piper WE, Steinberg PI. Predicting response to day treatment for personality disorder. *Can J Psychiatry*. 2011 Feb;56(2):110-7. PMID: 21333038.
44. Guimaraes C, Marra CA, Gill S, Simpson S, Meneilly G, Queiroz RH, **Lynd LD**. A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. *Patient Prefer Adherence*. 2010 Dec 8;4:433-40. doi:10.2147/PPA.S14217. PMID: 21301591.
45. Grindrod KA, **Lynd LD**, Joshi P, Rosenthal M, Isakovic A, Marra CA. Pharmacy owner and manager perceptions of pharmacy adaptation services in British Columbia. *Can Pharm J* 2011; 144(5):231-5.
46. Henrich N, Joshi P, Grindrod K, **Lynd LD**, Marra CA. Family physicians' perceptions of pharmacy adaptation services in British Columbia. *Can Pharm J* 2011; 144(4):172-8.
47. Oteng B, Marra F, **Lynd LD**, Ogilvie G, Patrick D, Marra CA. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening program. *Sex Transm Infect*. 2011 Feb;87(1):52-57. doi:10.1136/sti.2009.041392. PMID: 20956352.
48. Grindrod KA, Marra CA, Colley L, Tsuyuki RT, **Lynd LD**. Pharmacists' preferences for providing patient-centred services: a discrete choice experiment to guide health policy. *Ann Pharmacother*. 2010 Oct;44(10):1554-64. doi:10.1345/aph.1P228. PMID: 20841513.
49. Law MR, Morgran SG, Majumdar SR, **Lynd LD**, Marra CA. Effects of prescription adaption by pharmacists. *BMC Health Serv Res*. 2010 Nov 17;10:313. doi:10.1186/1472-6963-10.313. PMID: 21083922.
50. Kliber A, **Lynd LD**, Sin DD. The effects of long acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. *Resp Res*. 2010 May 11;11:56. doi:10.1186/1465-9921-11-56. PMID: 20459831.
51. Wilbur K, **Lynd LD**, Sadatsafavi M. Low molecular weight heparin versus Unfractionated Heparin for Prophylaxis of Venous Thromboembolism in Medicine Patients – A Pharmacoeconomic Analysis. *Clin Applied Thromb Hemostasis*. 2011 Oct;17(5):454-465. doi:10.1177/1076029610376935. PMID: 20699258.
52. **Lynd LD**, Marra CA, Najafzadeh M, Sadatsafavi M. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. *Pharmacoepidemiol Drug Saf*. 2010 Nov;19(11):1172 – 80. doi:10.1002/pds.1994. PMID: 20602338.
53. Johnson FR, Hauber AB, Ozdemir S, **Lynd L**. Quantifying Women's Stated Benefit-Risk Trade-Off Preferences for IBS Treatment Outcomes. *Value Health*. 2010 Jun-Jul;13(4):418-23. doi:10.1111/j.1524-4733.2010.00694.x. PMID: 20230550.
54. Marra F, **Lynd L**, Coombes M, Richardson K, Legal M, FitzGerald JM, Marra CA. Does antibiotic exposure during infancy lead to development of asthma? A systematic review and metaanalysis. *Chest*. 2009 Nov;135(5 Suppl):e30. PMID: 20162773.
55. **Lynd LD**, Najafzadeh M, Colley L, Byrne MF, Willan AR, Sculpher MA, Johnson RF, Hauber AB. Using the incremental net-benefit framework for quantitative benefit-risk analysis in regulatory decision making – a case study of alosetron in irritable bowel syndrome. *Value Health*. 2010 Jun-Jul;13(4):411-7. doi:10.1111/j.1524-4733.2009.00595.x. PMID: 19744297.

56. Guimaraes C, Marra CA, Simpson SH, Meneilly GS, Queiroz RHC, **Lynd LD**, Gill S. Exploring patients' perceptions for insulin therapy in type 2 diabetes: A Brazilian and Canadian qualitative study. *Patient Pref Adherence*. 2010 Jul 21;4:171-9. PMID: 20694179.
57. Thornton SJ, Wasan KM, **Lynd LD**, Wasan EK. Different financial barriers in treating VisceralLeishmaniasis in India (Bihar Region), Bangladesh, Nepal, Brazil, and Sudan. *Drug Dev Indust Pharm* 2010; 36 (11):1312-9.
58. Sadatsafavi M, **Lynd LD**, Marra CA, Carleton B, Tan WC, FitzGerald JM. Direct health care costs associated with asthma in British Columbia. *Can Resp J*. 2010 Mar-Apr;17(2):74-80. PMID: 20422063.
59. Simon LS, Strand CV, Boers M, Brooks PM, Tugwell PS, Bombardier C, Fries JF, Henry D, Goldkind L, Guyatt G, Laupacis A, **Lynd LD**, Macdonald T, Mamdani M, Moore A, Saag KG, Silman AJ, Stevens R, Tyndall A. How to ascertain drug safety in the context of benefit. Controversies and concerns. *J Rheumatol*. 2009 Sep;36(9):2114-21. doi: 10.3899/jrheum.090591. PMID: 19738223.
60. Grindrod KA, Rosenthal M, **Lynd LD**, Marra CA, Bougher D, Wilgosh C, Tsuyuki R. Pharmacist perspectives on providing chronic disease management services in the community (Part 1): Current Practice Environment. *Can Pharm J* 2009;142 (5); 234 – 9.
61. Rosenthal M, Grindrod KA, **Lynd LD**, Marra CA, Bougher D, Wilgosh C, Tsuyuki R. Pharmacist perspectives on providing chronic disease management services in the community (Part 2): Development & Implementation. *Can Pharm J* 2009;142 (6): 284 – 9.
62. Guimaraes C, Marra CA, Simpson SH, Meneilly GS, Queiroz RHC, **Lynd LD**. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. *Int J Technol Assess Health Care*. 2009 Jul;25(3):359-66. doi:10.1017/S0266462309990055. PMID: 19619355.
63. Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, Queiroz RHC, **Lynd LD**. Socioeconomic Differences in Preferences and Willingness-to-Pay for Insulin Delivery Systems in Type 1 and Type 2 Diabetes. *Diabetes Technol Ther*. 2009 Sep;11(9):567-73. doi:10.1089/dia.2009.0034. PMID: 19764835.
64. Tsang R, Colley L, **Lynd LD**. Inadequate statistical power to detect clinically significant differences in adverse events rates in randomized controlled trials. *J Clin Epi* 2009 ;62(6):609-16.
65. Bahadori K, Doyle-Waters MM, Marra C, **Lynd LD**, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. *BMC Pulm Med*. 2009 May 19;9:24. doi:10.1186/1471-2466-9-24. PMID: 19454036.
66. Marra F, Marra CA, Richardson K, **Lynd LD**, Kozyrskj A, Patrick DM, Bowie WR, FitzGerald JM. Antibiotic use in children is associated with increased risk of asthma. *Pediatrics*. 2009 Mar;123(3):1003-10. doi:10.1542/peds.2008-1146. PMID: 19255032.
67. Tsang R, Colley L, **Lynd LD**. Inadequate statistical power to detect clinically significant differences in adverse events rates in randomized controlled trials. *J Clin Epi* 2008 Nov 13. [Epub ahead of print].
68. McTaggart-Cowan HM, Shi P, Anis AH, FitzGerald JM, Kopec JA, Bai TR, Currie G, Soon JA, **Lynd LD**. An evaluation of patients' preferences for asthma therapy using a discrete choice experiment. *J Asthma* 2008; 45 (8): 630-8.
69. Sadatsafavi M, Najafzadeh M, **Lynd LD**, Marra CA. Reliability studies are not using enough observers for robust estimation of observer agreement: a simulation study. *J Clin Epidemiol* 2008;61(7):722-7.
70. **Lynd LD**, Richardson KJ, Pursell RA, Abu-Laban RB, Brubacher JR, Lepik KJ, Sivilotti ML. An evaluation of the osmole gap as a screening test for toxic alcohol poisoning. *BMC Emerg Med* 2008;28;8:5.
71. McTaggart-Cowan HM, Marra CA, Yang Y, Brazier JE, Kopec JA, Fitzgerald JM, Anis AH, **Lynd LD**. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. *Qual Life Res* 2008; 17(3): 453-62.

72. Ogrodniczuk JS, Joyce AS, **Lynd LD**, Piper WE, Steinberg PI, Richardson K. Predictors of premature termination of day treatment for personality disorder. *Psychother Psychosom* 2008; 77: 365-71.
73. Regier D, Marra CA, **Lynd LD**. Economic evaluations of anticoagulants for the prophylaxis of venous thromboembolism following major trauma. *Expert Rev Pharmacoecon Outcomes Res* 2007;7(4): 403-13.
74. Shalansky S, **Lynd LD**, Richardson K, Ignaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. *Pharmacotherapy*. 2007;27(9):1237-47.
75. **Lynd LD**, Goeree R, Crowther M, O'Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep vein thrombosis following major trauma. *Can J Clin Pharmacol*. 2007;14(2):e215-26.
76. Tan M, Regier DA, Esdaile JM, **Lynd LD**, Anis AH, Marra CA. Health economic evaluation: a primer for the practicing rheumatologist. *Arth Care Res* 2006;55(4):648-656.
77. Regier DA, Sunderji R, **Lynd LD**, Marra CA. Cost-effectiveness analysis of self-managed versus physician-managed oral anticoagulation therapy. *Can Med Assoc J* 2006; 174 (13): 1847-52.
78. Marra F, **Lynd LD**, Coombes M, Richardson K, Legal M, Fitzgerald JM, Marra CA. Does antibiotic exposure during infancy lead to development of asthma? A systematic review and meta-analysis. *Chest* 2006; 129: 610-18.
79. Marra CA, **Lynd LD**, Anis AH, Esdaile JM. Approval process and access to prescription drugs in Canada. *Arth Care Res* 2006; 55(1):9-11.
80. **Lynd LD**, Goeree R, O'Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. *Pharmacoeconomics* 2005; 23 (11): 1083 – 1106.
81. **Lynd LD**, Taylor J, Dobson R, Willison DJ. Prescription to over-the-counter deregulation in Canada: Are we ready for it, or do we need to be? *Can Med Assoc J* 2005; 173(7):775-7.
82. Willan AR, Pinto EM, O'Brien BJ, Kaul P, **Lynd LD**, Goeree R, Armstrong PW. Country-specific cost comparisons from multinational clinical trials: using empirical Bayesian shrinkage estimation. *Health Econ* 2005; 14: 327-38.
83. Purssell RA, **Lynd LD**, Koga Y. The use of the osmole gap as a screening test for the presence of exogenous substances: a review of the literature. *Toxicol Rev* 2004; 23 (3): 189-202.
84. Koga Y, **Lynd LD**, Purssell RA. A review of osmolality and molarity, applicable physical chemistry principles and recommendations to improve current practices. *Toxicol Rev* 2004; 23(3): 203-211.
85. **Lynd LD**, Sandford AJ, Kelly EM, Pare PD, Bai TR, Fitzgerald JM, Anis AH. Reconcilable differences - a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthma. *Chest* 2004; 164 (4): 1161-8.
86. Dobson R, Taylor J, **Lynd LD**. Are we ready for prescriptive authority? Lessons from the self-care example. *Can Pharm J* 2004; 137 (9):38-9.
87. Marra CA, **Lynd LD**, Esdaile JM, Kopec J, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. *Rheumatology (Oxford)*. 2004 Nov;43(11):1390-1397.
88. **Lynd LD**, O'Brien BJ. Taking calculated risks: advances in risk-benefit evaluation using probabilistic simulation methods. *J Clin Epidemiol* 2004; 57: 795-803.
89. **Lynd LD**, Warren L, Maclure M, Paré PD, Anis AH. Using administrative data to recruit study participants while protecting patient privacy: experience with "Camouflaged Sampling". *Eur J Epidemiol* 2004; 19: 517 - 25.
90. **Lynd LD**, O'Brien BJ. Cost-effectiveness of the implantable cardioverter-defibrillator: a review of the current evidence. *J Cardiovasc Electrophysiol* 2003; 14 (Suppl. 9): S99-S103.

91. **Lynd LD**, Guh DP, Paré PD, Anis AH. Patterns of inhaled asthma medication use: a 3 year longitudinal analysis of prescription claims data from British Columbia, Canada. *Chest* 2002; 122(6); 1973–1981.
92. **Lynd LD**. Use of inhaled anti-inflammatory medications for asthma: are they worth the cost? *J Inform Pharmacother* 2001;5:216-218.
93. Anis AH, **Lynd LD**, Wang XH, King G, Spinelli JJ, Fitzgerald M, Bai T, Parè PD. Double trouble: inappropriate asthma medication use linked to increased use of health care resources. *Can Med Assoc J* 2001; 164(5):625-31.
94. Gerber P, **Lynd LD**. Selective serotonin re-uptake inhibitor-induced movement disorders. *Ann Pharmacother* 1998; 32:692-698.
95. Gardner DM, **Lynd LD**. Sumatriptan and the serotonin syndrome. *Ann Pharmacother* 1998; 32(1): 33-38.
96. **Lynd LD**. Serotonin syndrome - a review of the drug-induced disease of the 90's. *Can Pharm J* 1997;130(6):31-4.
97. Marra CA, Carleton BC, **Lynd LD**, Marra F, McDougal AR, Chow D, McKerrow R. Drug and poison information resources on the internet, part 2: identification and evaluation. *Pharmacotherapy* 1996;16(5):806 - 818.
98. Marra CA, **Lynd LD**, McKerrow R, Carleton BC. Drug and poison resources on the internet, part 1: an introduction. *Pharmacotherapy* 1996; 16(4):537 - 546.
99. **Lynd LD**. Isotretinoin - are concerns with its long-term toxicity legitimate? *Can Pharm J* 1995; 128 (9): 23-4.
100. McCormack JP, **Lynd LD**, Pfeifer NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. *Can J Hosp Pharm* 1989;42 (1):3-9.

(b) *Conference Proceedings*

1. Raymakers AJN, **Lynd LD**, Bashir J. Management of the Riata Implantable Cardioverter Defibrillator (ICD) Lead Failure – A Cost-Effectiveness Analysis. Abstract accepted to the CADTH 2015 Symposium, Saskatoon, SK, April 12-14, 2015.
2. Rosenthal MM, Marra CA, Nakagawa B, Tsao NW, **Lynd LD**, Tsuyuki RT. Understanding pharmacy culture using the organizational culture profile. Poster presentation at the Canadian Pharmacists Association Conference, Saskatoon, SK, May 31-June 3, 2014.
3. Rosenthal MM, Marra CA, Nakagawa B, Tsao NW, **Lynd LD**, Tsuyuki RT. Understanding pharmacy culture using the big five inventory. Poster presentation at the Canadian Pharmacists Association Conference, Saskatoon, SK, May 31-June 3, 2014.
4. Tsao NW, Marra CA, **Lynd LD**, Gastonguay L, Nakagawa B. Impact of expanded pharmacy services on pharmacists' working conditions in British Columbia. Poster presentation at the Canadian Pharmacists Association Conference, Saskatoon, SK, May 31-June 3, 2014.
5. Sadatsafavi M, FitzGerald M, Marra C, De Vera M, Zafari Z, **Lynd L**. Comparative costs and effectiveness of asthma controller therapies after discharge from an asthma-related hospitalization. ISPOR 19th Annual International Meeting, Montreal, Quebec, May 31 – June 4, 2014.
6. Raymakers AJN, Marra CA, Sadatsafavi M, FitzGerald JM, Sin DD, **Lynd LD**. A population-based cohort study evaluating the association between inhaled corticosteroid use and lung cancer development in patients with COPD. CIHR Institute of Circulatory and Respiratory Health (ICRH) Young Investigators' Forum, Edmonton, Alberta, May 26-29, 2014. Won "Outstanding Poster Award".
7. Trenaman L, Almeida F, Ayas N, **Lynd LD**, Marra CA, Stacey D, Sadatsafavi M, Bansback N. Evaluating the potential cost-effectiveness of patient decision aids: A case study in obstructive sleep apnea. CADTH Symposium 2014. Ottawa, ON, April 6-8, 2014.

8. Zhang W, Guh D, Sun H, Marra CA, **Lynd LD**, Anis AH. The impact of price-cap regulations on exit by generic firms in Canada. iHEA/ECHE Congress 2014. Dublin, Ireland, July 13-16, 2014.
9. Mohammadi T, Guo N, Marra F, Khakban A, Campbell J, FitzGerald JM, **Lynd LD**, Marra CA. Comparing stated preferences and actual choices at individual level using Bayesian estimation: an application to latent tuberculosis infection treatment. iHEA/ECHE Congress 2014. Dublin, Ireland, July 13-16, 2014.
10. Lakzadeh P, Green TJ, McLean J, Talukder Z, Li K, **Lynd LD**. Factors Associated with Household Income in Rural Cambodia. Food Security Dialogue 2014. Edmonton, Alberta, April 30 – May 2, 2014.
11. Raymakers AJN, Marra CA, Sadatsafavi M, FitzGerald JM, Sin DD, **Lynd LD**. Inhaled corticosteroid (ICS) use in Chronic Obstructive Pulmonary Disease and Lung Cancer Diagnosis. Institute for Heart and Lung Health FEST 2014, Vancouver, BC, February 2014.
12. Rizzardo S, Bansback N, Mitton C, Marra C, **Lynd L**. Canadian Societal Views and Trade-Offs for Rare Disease Treatment. Oral presentation. 2014 CADTH Symposium, Hilton Lac-Leamy in the National Capital Region, Gatineau, Quebec, April 6-8, 2014.
13. Rizzardo S, Bansback N, Mitton C, Marra C, **Lynd L**. Rare Diseases Equity and Funding; A Canadian Perspective. Poster presentation. 2014 CADTH Symposium, Hilton Lac-Leamy in the National Capital Region, Gatineau, Quebec, April 6-8, 2014.
14. Wilcox E, Mitton C, **Lynd L**. Incorporating societal values into healthcare decision-making: Engaging publics in reimbursement decision-making for drugs for rare diseases. Oral presentation at 2014 CADTH Symposium, National Capital Region, ON, Canada, April 6-7, 2014.
15. Wilcox E, Mitton C, **Lynd L**. Engaging publics in reimbursement decision-making for drugs for rare diseases. Poster presentation. 25th Annual Canadian Bioethics Society conference, Vancouver, BC, Canada, May 29-31, 2014.
16. Rizzardo S, Bansback N, Mitton C, **Lynd L**. Values of the Canadian public towards pharmaceutical reimbursement decisions. Poster presentation. ISPOR 19th Annual International Meeting. Montreal, Quebec, May 31 – June 4, 2014. *Value in Health*;17(3):240.
17. Rizzardo S, Bansback N, Mitton C, Marra C, **Lynd L**. How Canadians value rare diseases given their opportunity cost. Podium presentation. ISPOR 19th Annual International Meeting, Montreal, Quebec, May 31 – June 4, 2014. *Value in Health*;17(3):10.
18. Zafari Z, Sadatsafavi M, FitzGerald JM, **Lynd LD**, Marra C. The humanistic and economic impact of following evidence-based asthma controller therapy: a simulation study. *Value in Health* 2013; 16(3): A235.
19. Patel A, Lester R, Ritvo P, Marra C, **Lynd LD**, Karanja S, Van der Kop M. Discriminative ability of the SF-12 in Kiswahili by HIV stage in Kenya. *Value in Health*; 16(3): A95.
20. Rizzardo S, **Lynd L**. Canadian values, attitudes and willingness to pay for expensive medications for rare diseases. Poster presentation. International Rare Diseases Research Consortium (IRDiRC), Dublin, Ireland, April 16-17, 2013.
21. Zafari Z, Thorlund K, FitzGerald M, Marra C, **Lynd LD**, Sadatsafavi M. Multiple-treatment comparison versus pairwise meta-analysis: Impact on the expected value of information results. iHEA 2013, Australia, July 7-10, 2013.
22. Rizzardo S, **Lynd L**. Canadian values, attitudes and willingness to pay for expensive medications for rare diseases. Poster presentation. 16th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Symposium, Vancouver, BC, Canada, June 11-14, 2013. *Journal of Pharmacy & Pharmaceutical Sciences*;16(3).
23. Wilcox E, Mitton C, **Lynd L**. Public engagement: Understanding and accounting for public values and perspectives in reimbursement decision-making to expensive drugs for rare diseases. Poster presentation. 2013 Vancouver Health Economics Methodology Meeting, Vancouver, BC, Canada, June 7, 2013.

24. Raymakers AJN, **Lynd LD**. A critical review of cost-effectiveness analyses of lung cancer screening with computed tomography. Institute for Heart and Lung Health (IHLH) Fest 2013. Vancouver, BC, February 21, 2013
25. Raymakers AJN, Marra CA, FitzGerald JM, Sadatsafavi M, Sin DD, **Lynd LD**. A population-based cohort study evaluating the association between inhaled corticosteroid use and lung cancer development in patients with COPD. Canadian Institutes of Health Research, Institute of Circulatory and Respiratory Health. May 2013.
26. Raymakers AJN, Sadatsafavi M, **Lynd LD**, FitzGerald JM. The Economic Burden of COPD: A Systematic Review. Canadian Agency for Drugs and Technologies in Health (CADTH), St. John's, NL, May 5-7, 2013.
27. Raymakers AJN, Bashir J, Cowan S, Yamashita M, **Lynd LD**. A Cost-Effectiveness Analysis of Alternative Management Strategies for the Sprint Fidelis Implantable Cardioverter-Defibrillator Recall: A Probabilistic Decision Analysis Model. Canadian Agency for Drugs and Technologies in Health (CADTH), St. John's, NL, May 5-7, 2013.
28. Talukder Z, McLean J, **Lynd LD**, Kroeun H, Green TJ. Household food security, dietary diversity, anemia, and anthropometric status of poor women farmers in Prey Veng Province, Cambodia: A cross-sectional study. Accepted. IUNS 20th International Congress of Nutrition. Granada, Spain, September 15-20, 2013.
29. McLean J, **Lynd L**, Talukder Z, Kroeun H, Lakzadeh P, Ly S, Green TJ. Nutrition knowledge, attitudes and cultural practices of rural women farmers in Prey Veng Province, Cambodia. Accepted. IUNS 20th International Congress of Nutrition. Granada, Spain, September 15-20, 2013.
30. Sweeney K, Grubisic M, Marra CA, Kendall R, Li L, **Lynd L**. Comparison in HRQOL between unicompartmental knee arthroplasty and total knee arthroplasty for the treatment of osteoarthritis. Global Oxford Masters Symposium. Oxford, UK, September 24-25, 2012.
31. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. The effect of the timing of oral hormonal emergency contraceptives on pregnancy rate. The 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (Poster Walk presentation). Barcelona, August 25-26, 2012.
32. Tsao NW, Rosenthal M, Thomas JM, Marra CA, **Lynd LD**, Tsuyuki R. Factors affecting community pharmacists' participation in pharmacy practice research. Poster presentation at Canadian Pharmacists Association National Conference June 2012.
33. **Lynd L**, Marra C, Sadatsafavi M. Safety of long-acting beta agonists (LABA) with or without inhaled corticosteroids in asthma. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Barcelona, Spain, August 23-26, 2012.
34. Bashir J, Cowan S, Yamashita M, Raymakers A, **Lynd LD**. Impact of Cost on the Management of the Spring Fidelis Recall. Heart Rhythm Society, St. Paul's Hospital, Vancouver, BC, 2012.
35. Raymakers AJN, McCormick N, FitzGerald JM, Marra CA, Sin D, **Lynd LD**. The Use of Inhaled Corticosteroids (ICS) in Chronic Obstructive Pulmonary Disease (COPD) Patients and Risk of Lung Cancer: A Systematic Review. 2012 American Thoracic Society (ATS) International Conference, San Francisco, CA. May 18-23, 2012.
36. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. Comparison of pregnancy rates after two hormonal emergency contraceptives. North American Forum on Family Planning. Washington, DC, October 22-24, 2011. (Contraception 2011;84:333-4.)
37. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. A population-based comparison of the effectiveness of two emergency contraceptives. The 6th Asian Conference on Pharmacoepidemiology 2011. Beijing, October 30, 2011.

38. Leung VWY, Soon JA, Marra CA, **Lynd LD**, Levine M. Adjudication of pregnancy-related health outcomes using administrative data. The 6th Asian Conference on Pharmacoepidemiology. Beijing, October 28-30, 2011.
39. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. The levonorgestrel and Yuzpe regimens of emergency contraceptives: a comparative effectiveness study. (Presentation) EC Jamboree 2011: Annual Meeting of the International Consortium for Emergency Contraception and the American Society for Emergency Contraception, New York City, October 4, 2011.
40. Sadatsafavi M, Bedouch P, FitzGerald JM, Marra CA, **Lynd LD**. Impact on direct health care costs associated with asthma of various controller medications: results from a population based cohort study. Submitted, 8th World iHEA Congress in Health Economics/International AllerGen Symposium on Asthma and Economics. Toronto, July 2011.
41. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra CA, **Lynd LD**. Trends in asthma-related direct medical costs in British Columbia, Canada. Submitted, 8th World iHEA Congress in Health Economics/International AllerGen Symposium on Asthma and Economics. Toronto, July 2011.
42. Leung VWY, Soon JA, Marra CA, **Lynd LD**, Levine M. History of regular hormonal contraceptive use among emergency contraceptive users in British Columbia. Canadian Association for Population Therapeutics Annual Conference. Ottawa, Ontario, April 17-19, 2011.
43. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. Comparison of pregnancy rates after two hormonal emergency contraceptives. North American Forum on Family Planning. Washington, DC, October 22-24, 2011.
44. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra C, **Lynd LD**. Initiation of controller medication in newly diagnosed asthma patients: impact on economic resource utilization. European Respiratory Society Annual Congress, Amsterdam, September 2011. Oral communication.
45. Sadatsafavi M, Bedouch P, FitzGerald JM, Marra C, **Lynd L**. Stepping up the controller medication in asthma patients: impact of various treatment options on costs. European Respiratory Society Annual Congress, Amsterdam, September 2011. Oral communication.
46. Najafzadeh M, **Lynd LD**, Davis JC, Bryan S, Anis A, Marra M, Marra CA. Barriers for integrating personalized medicine into clinical practice: a best worst scaling choice experiment. CADTH 2011 symposium April 3-5, 2011, Vancouver, BC. Oral presentation in the "Evidence to Practice: Maximizing Our Investment in Health Care" section, session C6, April 4th.
47. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra C, **Lynd L**. Health care costs of uncontrolled asthma: a population-based cohort study in British Columbia. Canadian Association for Population Therapeutics Annual Conference, Ottawa, ON, April 2011. Oral communication.
48. Sadatsafavi M, Bedouch P, FitzGerald JM, Marra C, **Lynd L**. Asthma-related direct medical costs in British Columbia from 2002 to 2007: a population-based cohort study. Canadian Association for Population Therapeutics Annual Conference, Ottawa, ON, April 2011. Oral communication.
49. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra C, **Lynd L**. Evolution of asthma-related direct medical costs in British Columbia from 2002 to 2007: a population-based cohort study. Heart + Lung Health Fest 2011, Vancouver (BC), March 8-12. (Awarded best poster)
50. Bedouch P, Sadatsafavi M, FitzGerald JM, Marra CA, **Lynd LD**. Calculating direct health care costs associated with asthma in British Columbia, 2002-2007. Allergen's 6th Annual Research Conference, Vancouver, British Columbia, February 6-8, 2011.
51. Marra CA, Harvard SS, Wilby K, De Silva J, **Lynd LD**. A randomized controlled trial evaluating pharmaglyph augmentation of patient information for HIV drugs. International Pharmaceutical Federation (FIP). Lisbon, Portugal, September 2010. (podium)

52. Najafzadeh M, Marra CA, **Lynd LD**, Sadatsafavi M, Sin DD. The economic value of a potential biomarker for chronic obstructive pulmonary disease. Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010.
53. Wong-Regier D, **Lynd LD**, Drummond M, Menon D. The value of patients' preferences in Health Economics. 15th Annual Meeting – International Society of Pharmacoeconomics and Outcomes Research. May 15 – 19, 2010. Issues Panel.
54. Marra C, **Lynd L**, Grindrod K, Joshi P, Isakovic A. An Overview of Pharmacy Adaption Services in British Columbia. Canadian Pharmacists Association Annual General Meeting in Calgary, AB (May 15-May 18, 2010) podium.
55. Marra C, **Lynd L**, Henrich N, Joshi P. Pharmacy Adaption Services in BC: The Physician Perspective. Canadian Pharmacists Association Annual General Meeting in Calgary, AB (May 15 - May 18, 2010) podium.
56. Sadatsafavi M, Marra CA, **Lynd LD**, Marra F, Liu J, Mendoza O, Tan M, Elwood KR, Fitzgerald JM. Benefit-risk analysis of isoniazid (INH) for treatment in latent tuberculosis infection (LTBI). Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010.
57. **Lynd LD**, Marra CA, Harvard S, Liu J, Najafzadeh M, FitzGerald JM, Sin D. Risk benefit analysis of LABA + ICS versus ICS alone for the treatment of asthma. Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010.
58. Marra C, Marra F, Richardson K, **Lynd LD**, FitzGerald JM. Are we treating wheeze with bug killer? Canadian Association for Population Therapeutics Annual Conference, Toronto, ON. March 28-30, 2010. (podium)
59. Najafzadeh M, Marra CA, **Lynd LD**, Sadatsafavi M, Sin DD. Economic value of potential biomarker for chronic obstructive pulmonary disease. Society for Medical Decision Making 31st Annual Meeting. Hollywood, CA. Oct 18 – 21, 2009.
60. **Lynd LD**, Marra CA, Grubisic M, Colley L. Using density plots to illustrate preference heterogeneity derived using a mixed logit model of discrete choice data. Society for Medical Decision Making 31st Annual Meeting. Hollywood, CA. Oct 18 – 21, 2009.
61. Sadatsafavi M, Marra CA, **Lynd LD**, Marra F, Liu J, Mendoza O, Tan M, Elwood K, FitzGerald JM. Benefit-risk analysis of isoniazid (INH) for treatment of latent class tuberculosis. Society for Medical Decision Making 31st Annual Meeting. Hollywood, CA. Oct 18 – 21, 2009.
62. Oteng B, Marra F, **Lynd L**, Marra CA. Societal preferences for the quadrivalent versus bivalent human papillomavirus vaccine. Health Technology Assessment International 6th Annual Meeting. Singapore, June 21-24, 2009.
63. Oteng B, Marra CA, **Lynd L**, Marra F. Societal preferences for the Human Papillomavirus vaccine. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual International Meeting, Orlando, Florida, May 16-20, 2009.
64. Marra F, Marra CA, Richardson K, **Lynd L**, Fitzgerald JM. What is the magnitude and pattern of antibiotic consumption in asthmatic children? American Thoracic Society, San Diego, California, May 18 - 24, 2009.
65. Grindrod K, Colley L, Marra CA, **Lynd LD**, Koehoorn M. Factors associated with taking antihypertensives: A population-based cross-sectional study of hypertensive individuals in the Canadian Community Health Survey. Canadian Association for Population Therapeutics Annual Conference, Montreal, QC. April 19-21, 2009.
66. Sweeney K, **Lynd LD**, Marra CA, Kendall R, Li L. Differences in health related quality of life following total and unicompartmental knee arthroplasty. Canadian Agency for Drugs and Technologies in Health 2009 Symposium. Ottawa, April 5-7, 2009. (Awarded best poster)
67. Oteng B, Marra CA, **Lynd L**, Ogilvie G, Patrick DM, Marra F. Evaluating societal preferences for the Human Papillomavirus vaccines using discrete choice experiment. Canadian Agency for Drugs and Technologies in Health 2009 Symposium. Ottawa, April 5-7, 2009.

68. **Lynd LD**, FitzGerald JM, Colley L, Soon JA. Establishing patients' preference weights for GINA criteria of asthma control using a discrete choice experiment. The Second Conjoint Analysis in Healthcare Conference, Delray Beach FL, March 24-26, 2009.
69. **Oteng B**, Marra CA, **Lynd LD**, Ogilvie G, Patrick D, Marra F. Evaluating Societal Preferences for the Human Papillomavirus Vaccines Using Discrete Choice Experiment. The Second Conjoint Analysis in Healthcare Conference, Delray Beach FL, March 24-26, 2009.
70. Grindrod K, Marra CA, Tsuyuki R, **Lynd LD**. Expanded scope of practice: What do pharmacists want? Vancouver Coastal Health Research Institute, Celebrate Research Week. March 2009.
71. Grindrod K, Colley L, Marra CA, **Lynd LD**, Koehoorn M. Factors associated with taking antihypertensives: A population-based cross-sectional study of hypertensive individuals in the Canadian Community Health Survey. Vancouver Coastal Health Research Institute, Celebrate Research Week. March 2009.
72. **Woolcott JC**, **Lynd LD**, Koehoorn M, Marra CA. An assessment of the construct validity of the Health Utilities Index Mark 3 in asthmatics using the population based Canadian Community Health Survey Cycle 3.1. Vancouver Coastal Health Research Institute, Celebrate Research, February 2009.
73. Marra F, Kaczorowski J, Marra CA, **Lynd L**, Tsuyuki R, Kendall P, Brunham RC. Pharmacy based immunization in rural communities' strategies. Pandemic Influenza Preparedness Strategic Planning Meeting, Winnipeg, Manitoba, November 6-8, 2008.
74. **Lynd LD**, FitzGerald M, Colley L, Soon J. Establishing Patients' Preference Weights for GINA Criteria of Asthma Control: A Discrete Choice Experiment. ISOQOL, October 22nd – 25th, 2008, Montevideo, Uruguay.
75. Maxwell CJ, Jantzi M, Poss J, Wodchis W, Hogan D, Supina A, **Lynd L**, Marra C, Hirdes JP. Construct validity of an observed health-related quality of life (HRQL) measure in Alzheimer's disease. (Oral Presentation) presented at the 15th Annual Conference of the International Society for Quality of Life Research, Montevideo Uruguay, Oct 22-25, 2008. Abstract published in Quality of Life Research 2008;A-13, Abstract #1504.
76. **Lynd LD**. Did the removal of rofecoxib from the market result in increased gastrointestinal risk for rheumatoid arthritis patients? A population based analysis. Annual European Congress of Rheumatology EULAR, Paris, France, June 11-14, 2008.
77. Rosenthal M, Grindrod K, **Lynd LD**, Marra CA, Wilgosh C, Bougher D, Tsuyuki RT. Study of Understanding Pharmacists' Perspectives on Remuneration and Transition towards Chronic Disease Management (SUPPORT- CDM): Qualitative Methods (Part 1 of 3). Presented at: Canadian Pharmacists Association Annual General Meeting in Victoria (May 31-June 3, 2008).
78. Grindrod K, Rosenthal M, **Lynd LD**, Marra CA, Wilgosh C, Bougher D, Tsuyuki RT. Study of Understanding Pharmacists' Perspectives on Remuneration and Transition towards Chronic Disease Management (SUPPORT- CDM): Challenges & Enablers (Part 2 of 3). Presented at: Canadian Pharmacists Association Annual General Meeting in Victoria (May 31-June 3, 2008).
79. Rosenthal M, Grindrod K, **Lynd LD**, Marra CA, Wilgosh C, Bougher D, Tsuyuki RT. Study of Understanding Pharmacists' Perspectives on Remuneration and Transition towards Chronic Disease Management (SUPPORT- CDM): Remuneration (Part 3 of 3). Presented at: Canadian Pharmacists Association Annual General Meeting in Victoria (May 31-June 3, 2008).
80. **Lynd, LD**, Lee A, FitzGerald JM, Soon J. The impact of socioeconomic status on self-reported quality of life in asthma. American Thoracic Society 2008 International Conference, Toronto, ON, May 18, 2008. (poster)
81. **Lynd, LD**, FitzGerald JM, Colley L, Soon J. Establishing patients' preference weights for GINA criteria of asthma control: A discrete choice experiment. American Thoracic Society 2008 International Conference, Toronto, ON, May 18, 2008. (presentation)
82. **Lynd LD**, Colley L, Najafzede M, Sculpher MJ, Willan AR, Johnson RF, Ozdemir S. Quantitative risk-benefit analysis of alosetron in irritable bowel syndrome: a patient-level meta-cohort analysis. *Pharmacoepi Drug Safety* 2007; 16: S183.

83. Hobbiger S, **Lynd LD**, Salek S. ISSUES PANEL: Benefit risk-modeling as an important component of good risk management. 43rd Annual Meeting, Drug Information Association. Atlanta, GA, USA. June 17-20, 2007.
84. Marra CA, **Lynd LD**, Bansback N, Guh D, Anis AH. Predicting preference-based measures from the HAQ-DI and the RAQoL. European League Against Rheumatism Annual European Congress of Rheumatology. Barcelona, Spain, June 13-16, 2007.
85. Marra CA, Marra F, Richardson K, **Lynd LD**, Kozyrskij A, Patrick D, Bowie W, FitzGerald JM. Does antibiotic exposure during infancy lead to development of asthma? A population based analysis. [Accepted]. 4th Canadian Therapeutics Congress. May 27 – 30. Halifax, NS.
86. Woolcott JC, **Lynd LD**, Koehoorn M, Marra CA. An assessment of the construct validity of the Health Utilities Index Mark 3 in asthmatics using the population based Canadian Community Health Survey Cycle 3.1. 4th Annual Canadian Therapeutics Congress. May 27 – 30. Halifax, NS.
87. **Lynd LD**, Marra CA. Development of an undergraduate course and 1-day workshop on Health Technology Assessment [accepted]. 2007 Canadian Agency for Drugs and Technologies in Health Symposium. April 23 – 24, 2007. Ottawa, ON.
88. Moride Y, **Lynd LD**, Abenheim L, Moore N, Kurz X, Hartford C. Methods for therapeutic risk benefit analysis. 22nd International Conference in Pharmacoepidemiology and Therapeutic Risk Assessment. August 25, 2006. Lisbon, Portugal. *Pharmacoepi and Drug Safety* 2006;15(suppl. 1): S1.
89. **Lynd LD**, Marra CA, Najafzadeh M, Sadatsafavi M. Risk benefit analysis of rofecoxib versus naproxen for the treatment of rheumatoid arthritis patients: a discrete event simulation. *Pharmacoepidemiology and Drug Safety* 2006; 15(Suppl. 1): S225.
90. McTaggart-Cowan HM, **Lynd LD**. Patients' preferences in the treatment of asthma: a review of the current evidence. American Thoracic Society Meeting, May 23, 2006. San Diego, CA.
91. **Lynd LD**, Marra CA, Najafzadeh M, Sadatsafavi M. Harm-benefit analysis of rofecoxib versus naproxen for the treatment of rheumatoid arthritis patients: a discrete event simulation. *Can J Clin Pharmacol* 2006; 13(1): e133.
92. McTaggart-Cowan HM, **Lynd LD**, Shi P, Marra CA, Anis AH, Soon JA, FitzGerald JM, Bai TR, Currie G. Evaluating treatment preferences in asthma using a discrete choice experiment. *Can J Clin Pharmacol* 2006; 13(1): e132.
93. McTaggart-Cowan HM, **Lynd LD**, Shi P, Marra CA, Ssozi V, Anis AH, Soon JA, FitzGerald JM, Bai TR, Currie G. A comparison of generic, indirect utility measures and disease-specific instruments in Asthma. *Can J Clin Pharmacol* 2006; 13(1): e136.
94. McTaggart-Cowan HM, Shi P, **Lynd LD**. Quantifying benefits and harms for treatment in asthma. *Canadian Respiratory Journal* 2006; 13(3): 158.
95. Johnson-Masotti AP, Fishman DN, **Lynd LD**, Sheehan D. A new decision-making framework for the prioritization of health technologies. *Health Services Restructuring: New Evidence and New Direction*. Queen's University, Kingston, ON, November 17-18, 2005.
96. **Lynd LD**, Sculpher MJ, Willan AR, Coombes ME, Rashidi AA. A systematic review and critical evaluation of risk-benefit analysis methods for therapeutic interventions. Society of Medical Decision Making Annual Meeting. October 2005. San Francisco, CA.
97. **Lynd LD**, Sculpher MJ, Willan AR, Coombes ME, Rashidi AA. A systematic review and critical evaluation of risk-benefit analysis methods for therapeutic interventions. International Conference on Pharmacoepidemiology. August 2005. Nashville, TN. *Pharmacoepi and Drug Safety*; 14 (Supp 2): S12.
98. **Lynd LD**, Willan A, Sculpher M, Coombes M. A systematic review of risk-benefit analytic methods applied in health care. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 46.

99. **Lynd LD**, Richardson K, Abu-Labban R, Brubacher J, Lepik K, Pursell R. An evaluation of diagnostic accuracy of the osmole gap for screening for toxic alcohol poisoning. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 45.
100. Marra C, **Lynd LD**, Richardson K, Coombes M, Marra F. Antibiotic exposure in infants and the development of asthma: a systematic review and meta-analysis. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 15.
101. Regier DA, Sunderji R, Gin K, **Lynd LD**, Marra CA. The cost-effectiveness of patient self-managed versus physician-managed oral anticoagulation: a Bayesian approach. Canadian Association of Population Therapeutics Annual Conference. April 17-19, 2005. Vancouver, BC. *Can J Clin Pharmacol* 2005; 12(1): 10.
102. **Lynd LD**, Goeree R, Crowther M, O'Brien BJ. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for DVT prophylaxis following major trauma. *Med Dec Making* 2004; 24 (5): 154.
103. **Lynd LD**, O'Brien BJ. Advances in risk-benefit evaluation using probabilistic simulation modeling. *Pharmacoeconomics and Drug Safety* 2004; 13 (Supp 1): S35.
104. Fisman DN, Johnson-Masotti A, **Lynd LD**, Sheehan D. Anonymous HIV testing in Canada: a cost-effective health intervention. American Public Health Association 132nd Annual Meeting and Exposition. Washington, DC. November 6-10, 2004.
105. **Lynd LD**, Cook D, O'Brien BJ. A risk-benefit analysis of enoxaparin versus unfractionated heparin for DVT prophylaxis post-trauma – a Bayesian perspective. *Exp Clin Cardiol* 2004; 9 (1): 65.
106. **Lynd LD**, Johnson-Masotti A, Sheehan D, Fisman DN. Anonymous HIV testing in Canada: a cost-effective health intervention. CDC STD Prevention Meeting, Philadelphia PA, March 8-11, 2004.
107. Marra CA, **Lynd LD**, Esdaile JM, Anis AH. The negative impact of low family income on health-related quality of life and physical function in patient with rheumatoid arthritis in a publicly funded health care environment. International Society of Quality of Life Research, 10th International Conference, Prague, Czech Republic, November 2003.
108. **Lynd LD**, O'Brien BJ. Taking calculated risks: advances in risk-benefit evaluation using probabilistic simulation methods. Canadian Institutes for Health Research. Strengthening the Foundations: Health Services and Policy Research Symposium. Montreal, QC. Nov. 22 – 24, 2003.
109. **Lynd LD**, O'Brien BJ. Taking calculated risks: advances in risk-benefit evaluation using probabilistic simulation methods. *Med Decis Making* 2003; 23 (6):560.
110. Shalansky SJ, **Lynd LD**, Ignaszewski A, Kerr C, Vickars L, Abd-Elmessih E. The effect of complementary and alternative medicine usage patterns on warfarin-related adverse events. *Can J Cardiol* 2003; 19 (Suppl A):164A.
111. Shalansky SJ, **Lynd LD**, Ignaszewski A, Kerr C, Vickars L. The risk of adverse events associated with complementary and alternative medicine amongst a cohort of patients taking warfarin. *Can J Cardiol* 2003; 19 (Suppl A): 163A.
112. **Lynd LD**, Paré PD, FitzGerald JM, Anis AH. Beyond drug therapy – an evaluation of the etiologic factors of the socioeconomic gradient in asthma control. *Can J Clin Pharmacol* 2003; 10(1):25.
113. Marra CA, **Lynd LD**, Esdaile JM, Anis AH. The relationship between socioeconomic status and quality of life/functional status in patients with rheumatoid arthritis. *Can J Clin Pharmacol* 2003; 10(1): 50.
114. Shalansky S, Neall E, Lo M, Abd-Elmessig T, Vickars L, **Lynd LD**. The impact of complementary and alternative medicine use on warfarin-related adverse outcomes. *Pharmacotherapy* 2002; 10:1245.

115. Purssell RA, **Lynd LD**, Brubacher J, Sivilotti M, Pudek M, Lepik K, Abu-Laban R, Koga Y. The osmolal gap as a screening test for toxic alcohol poisoning. The North American Congress of Clinical Toxicology 2002. Palm Springs, CA. Sept. 24 – 29, 2002.
116. **Lynd LD**, Paré PD, Fitzgerald JM, Anis AH. The association between proximate and contextual measures of socioeconomic status and magnitude of short-acting β -agonist use in asthma. *Can J Clin Pharmacol* 2002; 9(1): 79.
117. **Lynd LD**, Paré PD, Fitzgerald JM, Anis AH. Socioeconomic status and asthma control: a cross-sectional assessment of the association between social class and excessive short-acting β -agonist use in British Columbia, Canada. Drug Information Association 38th Annual meeting. Chicago, IL, USA. June 16 – 20, 2002.
118. **Lynd LD**, Paré PD, Fitzgerald JM, Anis AH. The association between proximate and contextual measures of socioeconomic status and magnitude of short-acting β -agonist use in asthma. Canadian Association for Population Therapeutics Annual Conference Year 2002. Toronto, ON, Canada. April 12 – 14, 2002.
119. **Lynd LD**, Guh D, Anis AH. Using administrative prescription data to enroll patients into clinical studies. International Society of Health Technology Assessment Annual Meeting. Philadelphia, PA, USA. June 3 – 6, 2001.
120. **Lynd LD**, Guh D, Paré PD, Anis AH. The standardized asthma-related quality of life questionnaire (AQLQ-S): does socioeconomic status affect measurements? *Value in Health* 2001; 4(2):75.
121. **Lynd LD**, Paré PD, Anis AH. Asthma-related quality of life: is there a social gradient in how asthmatics feel. *Can J Clin Pharmacol* 2001; 8(1):17.
122. **Lynd LD**, Paré PD, Anis AH. The social gradient of asthma-related morbidity: is disease severity the lone culprit? *Can J Clin Pharmacol* 2001; 8(1):38.
123. Warren L, Maclure M, Cassels A, Russwurm S, Carleton B, **Lynd LD**, Anis A. Finding study participants from administrative data without violating privacy: applications of camouflage sampling. The Wealth of Nations: Growth, Ideas and Technology. Western Economic Association International 75th Annual Conference. Vancouver, BC. June 29 – July 3, 2000.
124. Maclure M, **Lynd LD**, Warren LD, Paré P, Anis AH. 'Camouflaged sampling' using BC Ministry of Health data – recruiting while maintaining confidentiality. *Value in Health* 2000; 3(2):109.
125. **Lynd LD**, Raboud J, Guh D, Paré P, Anis AH. Trends in the use of β -agonist medications in British Columbia: an analysis of BC Pharmacare data. *Value in Health* 2000; 3(2):143.
126. Maclure M, **Lynd LD**, Warren LD, Paré P, Anis AH. 'Camouflaged sampling' using BC Ministry of Health data: a method of recruiting while preserving data privacy. *Can J Clin Pharmacol* 2000; 7(1):65.
127. **Lynd LD**, Raboud J, Guh D, Paré P, Anis AH. The use of β -agonist medications in British Columbia: an analysis of trends using BC Pharmacare data. *Can J Clin Pharmacol* 2000; 7(1):65.
128. **Lynd LD**. Drug-related mortality rates in British Columbia and Canada: an assessment of reported trends and data validity. 3rd International Conference on the Scientific Basis of Health Services. Toronto, Canada. Oct 1 – 3, 1999.

(c) *Other*

1. Cechetto D, Kenyon C, **Lynd LD**, Bishagara T, Ntahobakulira I, Rulisa S, Uwimana C, Silcox J, Davempport P, Haase P, Orchard C, Semanyenzi S, Tuyisenge G. An Evaluation of Health Care Quality in Rwanda 2010. Submitted to: Rwanda Ministry of Health, July 2011.
2. **Lynd LD**. Guidelines for schedule status submission for review by the National Drug Scheduling Advisory Committee (NDSAC) For: National Association of Regulatory Authorities.

3. **Lynd LD**, Marra CA. Expert review of benefit-risk assessment data submitted for Singulair® (montelukast sodium). For: Health Canada Therapeutic Products Directorate. March 31, 2006.
4. **Lynd LD**, Marra CA. Expert review of benefit-risk assessment data submitted for Accolate® (zafirlukast). For: Health Canada Therapeutic Products Directorate. March 31, 2006.
5. **Lynd LD**, Willan A, Sculpher M, Coombes M, Rashidi AA. Identification and evaluation of harm-benefit assessment methods. For: GlaxoSmithKline. August 8, 2005.
6. **Lynd LD**, Marra CA. A review of immunosuppressant strategies currently funded by the British Columbia Transplant Society. For: The British Columbia Transplant Society. April 8, 2002.

2. **NON-REFEREED PUBLICATIONS**

- (a) *Journals*
- (b) *Conference Proceedings*
- (c) *Other*

3. **BOOKS**

- (a) *Authored*
- (b) *Edited*
- (c) *Chapters*

4. **PATENTS**

5. **SPECIAL COPYRIGHTS**

6. **ARTISTIC WORKS, PERFORMANCES, DESIGNS**

7. **OTHER WORKS**

8. **WORK SUBMITTED (including publisher and date of submission)**

1. Sadatsafavi M, **Lynd LD**, De Vera MA, Zafari A, FitzGerald JM. Comparative effectiveness of asthma controller therapies after discharge from an asthma-related hospitalization. *Medical Care*, submitted March 2014.
2. Leung VWY, Soon JA, **Lynd LD**, Marra CA, Levine M. Population based evaluation of two regimens for emergency contraception: a comparative effectiveness study. *BMJ*, submitted February 2013.
3. Roy LM, Bansback N, Marra CA, Mulhern B, Bhatt J, Carr R, Chilvers M, **Lynd LD**. Infant respiratory Syncytial Virus health utility weights: time trade-off and best-worst scaling experiments. *Pediatrics*. Submitted Oct 2013.

9. **WORK IN PROGRESS (including degree of completion)**

1. **Lynd, LD**, Lee A, FitzGerald JM, Soon J. The impact of Socioeconomic status on self-reported quality of life in asthma. Manuscript 90% complete.

2. **Lynd, LD**, FitzGerald JM, Colley L, Soon J. Establishing patients' preference weights for GINA criteria of asthma control: A discrete choice experiment. Analysis complete. Manuscript 90% complete.